KR100930326B1 - Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same - Google Patents

Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same Download PDF

Info

Publication number
KR100930326B1
KR100930326B1 KR1020090038844A KR20090038844A KR100930326B1 KR 100930326 B1 KR100930326 B1 KR 100930326B1 KR 1020090038844 A KR1020090038844 A KR 1020090038844A KR 20090038844 A KR20090038844 A KR 20090038844A KR 100930326 B1 KR100930326 B1 KR 100930326B1
Authority
KR
South Korea
Prior art keywords
usa
tocopherol
chitosan
nucleic acid
group
Prior art date
Application number
KR1020090038844A
Other languages
Korean (ko)
Inventor
오유경
노상명
한수은
Original Assignee
고려대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단 filed Critical 고려대학교 산학협력단
Priority to KR1020090038844A priority Critical patent/KR100930326B1/en
Application granted granted Critical
Publication of KR100930326B1 publication Critical patent/KR100930326B1/en
Priority to PCT/KR2010/002838 priority patent/WO2010128793A2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G19/00—Compounds of tin
    • C01G19/02—Oxides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

PURPOSE: A cationic chitosan derivative which is bound with lipid-soluble vitamin or its derivative is provided to enhance the efficiency of transporting pharmaceutically effective ingredient into cells and improve treatment efficiency of the effective ingredient. CONSTITUTION: A cationic chitosan derivative has a structure of the chemical formula 1 or 2. The cationic chitosan derivative is prepared by reacting chitosan with lipid soluble vitamin using a coupling agent or protection group under the presence of a solvent. The protection group is phthalic anhydride. The reaction is performed under the presence of nucleophilic catalyst, DMAP[4-(Dimethylamino)pyridine]. A drug delivery system contains pharmaceutically effective ingredient and cationic chitosan derivative. The pharmaceutically effective ingredient is oligo nucleic acid. The drug delivery system has the form of liposome, micelle, emulsion, or nanoparticle.

Description

지용성 비타민 및 그 유도체로 유도된 신규한 양이온성 키토산, 그의 제조 방법 및 그를 포함하는 약물 전달체{Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same}Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same}

본 발명은 키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합된 양이온성 키토산 유도체, 그의 제조 방법 및 이를 포함하는 약물 전달체에 관한 것으로서, 본 발명의 양이온성 키토산 유도체는 세포 내로 전달하고자 하는 약제학적 유효성분을 세포 내로 수송하는 효율을 현저히 증강시킬 뿐만 아니라, 세포 독성을 감소시켜 약제학적 유효성분의 치료 효능을 증강시키는 용도로 유용하게 사용된다.The present invention relates to a cationic chitosan derivative in which chitosan or a derivative thereof is combined with a fat-soluble vitamin or a derivative thereof, a method for preparing the same, and a drug carrier comprising the same, wherein the cationic chitosan derivative of the present invention is pharmaceutically effective for delivery into cells. Not only significantly enhances the efficiency of transporting the components into the cell, but also is useful for the purpose of reducing the cytotoxicity to enhance the therapeutic efficacy of the pharmaceutical active ingredient.

유전 질환자들의 세포 내로 정상적인 유전자 서열을 삽입해서 유전성 질병을 처치하는데 사용할 수 있는 기술이 제안된 이후로 유전자 처치에 의한 다양한 유전적 장애를 치료하려는 시도들이 있어 왔다. 또한 최근에는 플라스미드 데옥시리보핵산 (plasmid DNA), 작은 간섭 이중나선 리보핵산(siRNA), 마이크로 리보핵 산(micro RNA), 안티센스 올리고 핵산(antisense oligonucleotide) 등 각종 핵산 물질의 의약적 용도가 규명됨에 따라서 이들 핵산 물질들을 세포 내로 효율적으로 전달하는 핵산 전달 물질의 중요성도 증대되고 있다. Since a technique has been proposed that can be used to treat hereditary diseases by inserting normal gene sequences into cells of genetically ill people, there have been attempts to treat various genetic disorders caused by gene therapy. In recent years, medicinal uses of various nucleic acid materials such as plasmid deoxyribonucleic acid (plasmid DNA), small interfering double-stranded ribonucleic acid (siRNA), microribonucleic acid (microRNA), and antisense oligonucleotides have been identified. Therefore, the importance of nucleic acid delivery materials for efficiently delivering these nucleic acid materials into cells is also increasing.

각종 세포내로 유전자를 전달하기 위하여 다양한 기술 및 운반체, 특히 벡터들이 제안되어 왔으나, 핵산의 전달 또는 발현을 위해 사용되는 기술은 크게 바이러스성 벡터와 비바이러스성 벡터를 이용한 방법으로 구분할 수 있다. 특히, 상기 비바이러스성 벡터 중 양이온성 리포좀 또는 양이온성 고분자들은 구조적인 특징에 의한 양하전으로 유전자의 음이온성 하전과 결합하여 복합체를 형성하는 특징이 있어 유전자 전달체로서 연구되어 왔다. Various techniques and carriers, particularly vectors, have been proposed for transferring genes into various cells, but techniques used for delivery or expression of nucleic acids can be largely divided into methods using viral and non-viral vectors. In particular, cationic liposomes or cationic polymers in the non-viral vector have been studied as gene carriers because they have a characteristic of forming a complex by binding to the anionic charge of a gene by positive charges due to structural features.

이러한 합성 물질을 이용한 유전자 전달 방법은 렌티바이러스나 아데노 바이러스 등을 사용한 바이러스성 유전자 수송체에 비하여 제조방법이 간편하고, 전달하려는 유전자의 크기가 제한을 받지 않으며, 바이러스 캡시드 단백질에 의한 반복투여시의 면역부작용이 적고, 바이러스 자체가 소유하는 유전자에 의한 체내 안전성 문제가 제기되지 않으며, 제조비용이나 시간에 있어서도 상업적으로 유리한 장점이 있다. Gene delivery methods using such synthetic materials are simpler to manufacture than viral gene transporters using lentiviruses or adenoviruses, and are not limited in size to the genes to be delivered, and are repeatedly administered by viral capsid proteins. There is little immune side effect, no safety problems caused by the genes owned by the virus itself, and there is a commercially advantageous advantage in terms of manufacturing cost or time.

양이온성 물질을 이용한 유전자 전달방법 중 양이온성 고분자 수송체의 경우 DEAE 덱스트란(dextran), 라이신 아미노산이 반복되는 구조의 폴리라이신, 에틸렌이민이 반복되는 구조의 폴리에틸렌이민, 또는 폴리아미도아민(polyamidoamine) (미국특허 제6,020,457호) 등이 유전자의 수송체로 연구되어 왔다. 그러나 이를 이용한 수송체 경우에는 세포 표면의 수용체를 통하여 효과적으로 수송되는 바이러스 성 수송체에 비하여 체내 세포 내로의 수송 효율이 낮다는 문제점이 지적되어 왔다. The cationic polymer transporter in the gene transfer method using a cationic material is DEAE dextran, polylysine having a repeating structure of lysine amino acid, polyethyleneimine having a repeating structure of ethyleneimine, or polyamidoamine (US Pat. No. 6,020,457) and the like have been studied as transporters of genes. However, it has been pointed out that in the case of the transporter using the same, the transport efficiency into the cells in the body is lower than that of the viral transporter that is effectively transported through the cell surface receptor.

한편 양이온성 인지질 수송체의 경우 인지질 조성에 양하전의 지질을 일정 비율로 혼합하여 양이온성 리포좀 (cationic liposome)과 같은 나노 크기의 입자를 제조하고 이 입자를 유전자와 혼합하여 양하전 인지질 입자와 유전자의 복합체를 세포주들에 처리하여 유전자의 발현을 증강시키는 방법이 사용되어 왔다(미국특허 제5,858,784호). On the other hand, in the case of cationic phospholipid transporters, nanocharged particles such as cationic liposomes are prepared by mixing positively charged lipids in a phospholipid composition and mixing these particles with genes to complex positively charged phospholipid particles with genes. Has been used to enhance the expression of genes by treating them with cell lines (US Pat. No. 5,858,784).

양이온성 지질들은 4차 아민, 3차 아민, 또는 하이드록시 에틸화 4차 아민 등이 지질의 헤드 부분에 연결되어 한 개의 양전하를 제공하는 종류 (DC-Chol, DDAB, TMAC 등)와 스퍼민(spermine) 등의 다중 아민(polyamine) 물질이 연결되어 여러 개의 양전하를 제공하는 종류로 구분될 수도 있다. Cationic lipids are those in which quaternary amines, tertiary amines, or hydroxyethylated quaternary amines are linked to the head of the lipid to provide one positive charge (DC-Chol, DDAB, TMAC, etc.) and spermine. Polyamines, such as) may be divided into a kind that is connected to provide a plurality of positive charges.

비바이러스성 벡터 중 양이온성 고분자는 렌티바이러스나 아데노 바이러스 등의 바이러스성 핵산 수송체에 비하여 제조방법이 간편하고, 바이러스 캡시드 단백질에 의한 반복투여시의 면역부작용이 적고, 바이러스 자체가 소유하는 유전자에 의한 체내 안전성 문제가 제기되지 않으며, 제조비용 또는 제조 공정에 있어서도 산업적으로 유리한 장점이 있다. Cationic polymers in non-viral vectors are simpler to manufacture than viral nucleic acid transporters such as lentiviruses and adenoviruses, have less immune side effects upon repeated doses by viral capsid proteins, and are resistant to genes owned by the virus itself. It does not pose a safety problem due to the body, there is an industrially advantageous advantage in the manufacturing cost or manufacturing process.

그러나, 종래에 개시된 여러 핵산 전달용 양이온성 고분자들은 합성 방법, 세포 독성 및 세포내 핵산 전달 효율 면에서 아직 보완되어야 할 점이 많다. 그러므로 합성 공정이 짧고, 세포 독성이 낮으면서도 세포 내로 효율적으로 핵산 물질들을 전달하는 전달체의 개발이 절실히 요구된다. However, many disclosed cationic polymers for nucleic acid delivery still need to be supplemented in terms of synthesis method, cytotoxicity and intracellular nucleic acid delivery efficiency. Therefore, there is an urgent need for the development of a transporter that delivers nucleic acid materials efficiently into cells while having a short synthetic process and low cytotoxicity.

이에 본 발명자들은 세포에 대한 낮은 독성과 우수한 약제학적 유효성분, 특히 핵산의약물 전달 효율을 가지는 전달체를 개발하기 위하여 양전하를 가지는 키토산과 지용성 비타민 중 대표적인 레티놀 및 레티놀 유도체와 에르고칼시페롤 및 에르고칼시페롤 유도체, 콜레칼시페롤 및 콜레칼시페롤 유도체, 토코페롤 및 토코페롤 유도체, 토코트리엔올 및 토코트리엔올 유도체를 이용하여 신규한 지용성 비타민 및 그 유도체 비타민들을 수식한 신규한 양이온성 키토산을 합성하였으며 이 양이온성 키토산을 포함한 핵산 전달체의 경우 사람의 암 세포주 및 쥐의 세포주에서 약제학적 유효성분의 전달 효율을 현저히 증가시킬 뿐만 아니라 세포 독성도 현저하게 감소시키는 것을 확인함으로써, 본 발명을 완성하였다.In order to develop a carrier having low toxicity and excellent pharmaceutical effective ingredients, in particular, a nucleic acid drug delivery efficiency, the present inventors have shown typical retinol and retinol derivatives, ergocalciferol and ergocal among chitosan and fat-soluble vitamins having a positive charge. A novel cationic chitosan modified with a novel fat-soluble vitamin and its derivative vitamins using ciperol derivatives, cholecalciferol and cholecalciferol derivatives, tocopherol and tocopherol derivatives, tocotrienols and tocotrienol derivatives The present invention was completed by confirming that the nucleic acid carrier containing the cationic chitosan not only significantly increased the efficiency of delivery of the pharmaceutical active ingredient but also significantly reduced cytotoxicity in human cancer cell lines and mouse cell lines. .

본 발명의 목적은 세포 내로 약제학적 유효성분의 전달을 증강시키는데 사용될 수 있는 키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합된 양이온성 키토산 유도체 및 그의 제조 방법을 제공하는 것이다. It is an object of the present invention to provide a cationic chitosan derivative in which chitosan or a derivative thereof is combined with a fat soluble vitamin or a derivative thereof which can be used to enhance delivery of a pharmaceutical active ingredient into a cell, and a method for producing the same.

본 발명의 다른 목적은 Another object of the present invention

약제학적 유효성분; 및Pharmaceutical active ingredients; And

키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합된 양이온성 키토산 유도체를 포함하는 약물 전달체를 제공하는 것이다. The present invention provides a drug delivery agent comprising a cationic chitosan derivative in which chitosan or a derivative thereof is combined with a fat-soluble vitamin or a derivative thereof.

본 발명의 또 다른 목적은 Another object of the present invention

본 발명에 따른 상기 약물 전달체; 및The drug carrier according to the present invention; And

약제학적으로 허용 가능한 담체를 포함하는 의약 조성물을 제공하는 것이다. It is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

본 발명의 또 다른 목적은 Another object of the present invention

기재;materials;

상기 기재 상에 코팅된 본 발명에 따른 양이온성 키토산 유도체; 및Cationic chitosan derivatives according to the invention coated on the substrate; And

상기 양이온성 키토산 유도체와 결합된 핵산 앱타머를 포함하는 진단 키트를 제공하는 것이다.It is to provide a diagnostic kit comprising a nucleic acid aptamer coupled with the cationic chitosan derivative.

본 발명은 키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합된 양이온성 키토산 유도체에 관한 것이다.The present invention relates to a cationic chitosan derivative in which chitosan or a derivative thereof is combined with a fat soluble vitamin or a derivative thereof.

본 발명에 의한 상기 양이온성 키토산 유도체는 미셀, 나노입자 등의 형태로 제제화되어 전달하고자 하는 약물의 사용 목적에 따라 어떠한 동물 세포로도 약물 전달이 가능할 뿐만 아니라, 목적하는 약물의 수송 효율을 현저히 증강시킬 수 있으며 세포에 대한 독성 역시 감소시킨다. The cationic chitosan derivatives according to the present invention are formulated in the form of micelles, nanoparticles, and the like, and are capable of drug delivery to any animal cell according to the purpose of use of the drug to be delivered, and significantly enhance the transport efficiency of the desired drug. It also can reduce the toxicity to cells.

본 발명에 의한 양이온성 키토산 유도체는 키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합한 것은 모두 포함된다. 여기서 사용된 용어 "결합"이란 화학적 공유 결합을 의미하는 것으로서, 보다 구체적으로 키토산 또는 그 유도체에 존재하는 하이드록시기(-OH) 또는 아민기(-NH2)와 같은 관능기가 비타민 또는 그 유도체에 존재하는 하이드록식(-OH) 또는 카르복실기(-COOH)와 같은 관능기와 화학적 반응을 통하여 결합한 것을 의미한다. The cationic chitosan derivative according to the present invention includes all chitosan or derivatives thereof combined with fat-soluble vitamins or derivatives thereof. As used herein, the term "bond" refers to a chemical covalent bond, and more specifically, a functional group such as a hydroxy group (-OH) or an amine group (-NH 2 ) present in chitosan or a derivative thereof is added to a vitamin or a derivative thereof. It means that the functional groups such as hydroxyl (-OH) or carboxyl group (-COOH) present by the chemical reaction.

일 구체예에서 상기 양이온성 키토산 유도체는 하기 화학식 1 또는 화학식 2의 구조로 표현될 수 있다. In one embodiment, the cationic chitosan derivative may be represented by the structure of Formula 1 or Formula 2.

[화학식 1][Formula 1]

Figure 112009026795293-pat00001
Figure 112009026795293-pat00001

[화학식 2][Formula 2]

Figure 112009026795293-pat00002
Figure 112009026795293-pat00002

상기 식에서 R은 지용성 비타민 또는 그 유도체로부터 유도된 유기기를 나타내고, Wherein R represents an organic group derived from a fat-soluble vitamin or a derivative thereof,

L은 -CONH- 또는 -NHCOO-을 나타내고,L represents -CONH- or -NHCOO-,

M은 -COO- 또는 -O(CH2)2O-를 나타내며, M represents -COO- or -O (CH 2 ) 2 O-,

X는 아세틸기, 메틸글리콜기, 갈락토실기, 락토실기 또는 말토실기를 나타내고,X represents an acetyl group, methyl glycol group, galactosyl group, lactosyl group or maltosyl group,

a 및 b는 각각 독립적으로 1내지 150의 정수를 나타내며, a and b each independently represent an integer of 1 to 150,

c는 0내지 50의 정수를 나타내고,c represents an integer of 0 to 50,

n은 1 내지 4의 정수를 나타낸다. n represents the integer of 1-4.

일 구체 예에서 상기 R은 레티놀(retinol), 9-시스-레티놀산(9-cis-retinoic acid), 13-시스-레티놀산(13-cis-retinoic acid), 올-트랜스-레티놀산(all-trans-retinoic acid), 에르고칼시페롤(ergocalciferol, vitamin D2), 비타민 D2 (6,19,19-d3)(Vitamin D2 (6,19,19-d3)), 콜레칼시페롤(cholecalciferol, vitamin D3), 비타민 D3 (6,19,19-d3)(vitamin D3 (6,19,19-d3)), (±)-알파-토코페롤((±)-α-tocopherol), (+)-알파-토코페롤((+)-α-tocopherol), (+)-베타-토코페롤((+)-β-tocopherol), 감마-토코페롤((+)-γ-tocopherol), 델타-토코페롤((+)-δ-tocopherol), 알파-토코페롤 숙시네이트(D-α-tocopherol succinate), 알파-토코페롤 폴리에틸렌글리콜(D-α-tocopherol polyethylene glycol), 알파-토코트리엔올(D-α-tocotrienol), (+)-베타-토코트리엔올((+)-β-tocotrienol), 델타-토코트리엔올(D-δ-tocotrienol), 및 감마-토코트리엔올(D-γ-tocotrienol)로 이루어진 그룹 중에서 선택된 비타민 또는 그 유도체로부터 유도된 유기기를 나타내나 이에 제한되지 않는다.In one embodiment the R is retinol, 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid (all -trans-retinoic acid), ergocalciferol (vitamin D2), vitamin D2 (6,19,19-d3) (Vitamin D2 (6,19,19-d3)), cholecalciferol, vitamin D3), vitamin D3 (6,19,19-d3) (vitamin D3 (6,19,19-d3)), (±) -alpha-tocopherol ((±) -α-tocopherol), (+)- Alpha-tocopherol ((+)-α-tocopherol), (+)-beta-tocopherol ((+)-β-tocopherol), gamma-tocopherol ((+)-γ-tocopherol), delta-tocopherol ((+) -δ-tocopherol), D-α-tocopherol succinate, D-α-tocopherol polyethylene glycol, D-α-tocotrienol, ( Group consisting of +)-beta-tocotrienol ((+)-β-tocotrienol), delta-tocotrienol (D-δ-tocotrienol), and gamma-tocotrienol (D-γ-tocotrienol) Vita selected from Organic groups derived from min or derivatives thereof, but are not limited thereto.

다른 구체 예에서 상기 화학식 1 또는 화학식 2의 화합물은 c가 0인 화합물을 포함한다.In another embodiment, the compound of Formula 1 or Formula 2 includes a compound wherein c is 0.

또 다른 구체 예에서 상기 화학식 1 또는 화학식 2의 화합물은 c는 1내지 50이고, X는 갈락토실, 락토실 또는 말토실을 나타내는 화합물을 포함한다.In another embodiment, the compound of Formula 1 or Formula 2 includes a compound wherein c is 1 to 50 and X represents galactosyl, lactosyl or maltosyl.

또 다른 구체 예에서 상기 화학식 1 또는 화학식 2의 화합물은 In another embodiment the compound of Formula 1 or Formula 2 is

a와 b의 합이 2내지 50이고, the sum of a and b is 2 to 50,

R은 9-시스-레티놀산(9-cis-retinoic acid), 13-시스-레티놀산(13-cis-retinoic acid), 올-트랜스-레티놀산(all-trans-retinoic acid), (±)-알파-토코페롤((±)-α-tocopherol), 알파-토코페롤 숙시네이트(D-α tocopherol succinate), (+)-알파-토코페롤((+)-α-tocopherol), 알파-토코페롤 폴리에틸렌글리콜(D-α- tocopherol polyethylene glycol), 및 알파-토코트리엔올(D-α-tocotrienol)로 이루어진 그룹 중에서 선택된 비타민 또는 그 유도체로부터 유도된 유기기를 나타내는 화합물을 포함한다.R is 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid, (±) -Alpha-tocopherol ((±) -α-tocopherol), alpha-tocopherol succinate, (+)-alpha-tocopherol ((+)-α-tocopherol), alpha-tocopherol polyethylene glycol ( D-α-tocopherol polyethylene glycol), and alpha-tocotrienol (D-α-tocotrienol) includes a compound exhibiting an organic group derived from a vitamin or a derivative thereof.

본 발명은 또한 용매의 존재 하에, 커플링제(coupling agent) 또는 보호기를 사용하여 키토산 또는 그 유도체를 지용성 비타민 또는 그 유도체와 반응시키는 단계를 포함하는 양이온성 키토산 유도체의 제조방법에 관한 것이다.The present invention also relates to a method for preparing a cationic chitosan derivative comprising reacting chitosan or a derivative thereof with a fat soluble vitamin or a derivative thereof in the presence of a solvent using a coupling agent or protecting group.

상기 커플링제(coupling agent)는 특별히 제한되지 않으며, 결합시키고자 하는 관능기의 종류에 따라 사용 가능한 커플링제의 종류는 공지되어 있다. 예를 들어 EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide), DCC(Dicyclohexylcarbodiimide) DIC(diisopropylcarbodiimide), CDI(1,1'-Carbonyldiimidazole), 숙신이미딜 포밀벤조산(SFB, succinimidyl 4-formylbenzoate), C6-숙신이미딜 포밀벤조산(C6-SFB, C6-succinimidyl 4-formylbenzoate), 디숙신이미딜 글루탐산(DSG, Disuccinimidyl glutarate), 디숙신이미딜 수베르산(DSS, Disuccinimidyl suberate), 비스설포숙신이미딜 수베르산(BS3, Bis[sulfosuccinimidyl] suberate), HOBt(N-Hydroxybenzotriazole), 무수숙신산(succinic anhydride), NHS(N-hydroxysuccinimide) 및 sulfo-NHS로 이루어진 그룹 중에서 선택된 하나 이상을 사용할 수 있다.The coupling agent (coupling agent) is not particularly limited, the type of coupling agent that can be used depending on the type of functional group to be bonded is known. For example, EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide), DCC (Dicyclohexylcarbodiimide) DIC (diisopropylcarbodiimide), CDI (1,1'-Carbonyldiimidazole), succinimidyl formylbenzoate (SFB, succinimidyl 4-formylbenzoate ), C6-succinimidyl formylbenzoic acid (C6-SFB, C6-succinimidyl 4-formylbenzoate), disuccinimidyl glutarate (DSG), disuccinimidyl suberate (DSS, Disuccinimidyl suberate), bissulfo One or more selected from the group consisting of succinimidyl suveric acid (BS3, Bis [sulfosuccinimidyl] suberate), HOBt (N-Hydroxybenzotriazole), succinic anhydride, NHS (N-hydroxysuccinimide) and sulfo-NHS can be used. have.

또한 상기 보호기 역시 특별히 제한되지 않으며, 보호시키고자 하는 관능기의 종류에 따라 사용 가능한 보호기의 종류는 공지되어 있다. 예를 들어 무수프탈 산을 사용할 수 있다.In addition, the protecting group is also not particularly limited, and the type of protecting group that can be used depending on the type of functional group to be protected is known. For example, phthalic anhydride can be used.

또한 상기 반응은 필요에 따라 친핵성 촉매의 존재 하에 진행될 수 있다. 상기 친핵성 촉매 역시 당업계에 공지되어 있으며 예를 들어 DMAP(4-(Dimethylamino)pyridine)을 사용 할 수 있다.The reaction can also proceed in the presence of a nucleophilic catalyst as needed. Such nucleophilic catalysts are also known in the art and may use, for example, DMAP (4- (Dimethylamino) pyridine).

본 발명은 또한 약제학적 유효성분; 및The present invention also provides a pharmaceutical active ingredient; And

키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합된 양이온성 키토산 유도체를 포함하는 약물 전달체에 관한 것이다. The present invention relates to a drug carrier comprising a cationic chitosan derivative in which chitosan or a derivative thereof is combined with a fat-soluble vitamin or a derivative thereof.

본 발명에 따른 약물 전달체는 다양한 세포들에서 약물의 세포내 수송도를 증가시킬 뿐만 아니라 세포 독성도 현저하게 감소시키므로, 예를 들어 올리고 핵산 의약을 포함하는 약물을 이용한 치료요법 등에 효과적으로 사용 가능하다. Since the drug carrier according to the present invention not only increases the intracellular transport of the drug in various cells but also significantly reduces the cytotoxicity, it can be effectively used, for example, in the therapy with the drug including the oligonucleotide medicine.

또한 본 발명의 약물 전달체는 양하전을 띠게 되므로, 약물 전달체의 양하전과 음전하로 하전된 의약물의 단순한 혼합(mix)에 의해 정전기 결합을 통해 약물 전달체와 의약물 간의 복합체를 효율적으로 형성할 수 있다. In addition, since the drug carrier of the present invention is positively charged, it is possible to efficiently form a complex between the drug carrier and the drug through electrostatic bonding by a simple mix of the positively and negatively charged drugs of the drug carrier.

상기 약제학적 유효성분은 화학요법제, 단백질 의약 또는 핵산의약을 포함한다. 상기 약제학적 유효성분은 바람직하게는 음전하로 하전된 것이거나 음하전으로 유도될 수 있는 것을 포함한다. The pharmaceutical active ingredient includes a chemotherapeutic agent, a protein medicine or a nucleic acid medicine. The pharmaceutical active ingredient is preferably negatively charged or include those that can be induced negatively charged.

상기 화학요법제는 임의의 질환에 대한 약리 효과를 나타내는 유기 화합물을 의미한다. 이러한 화학요법제의 대표적인 예로는 항암 화학요법제를 들 수 있다. 공지의 항암 화학요법제로는 예를 들어, 파클리탁셀(paclitaxel), 도세탁셀(docetaxel), 시스플라틴(cisplatin), 카르보플라틴(carboplatin), 옥살리플라틴(oxaliplatin), 독소루비신 (doxorubicin), 다우노루비신(daunorubicin), 에피루비신(epirubicin), 이다루비신(idarubicin), 발루비신(valubicin), 미토산트론(mitoxantrone), 커큐민(curcumin), 제피티닙(gefitinib), 에를로티닙(erlotinib), 이리노테칸(irinotecan), 토포테칸(topotecan), 빈블라스틴(vinblastine), 빈크리스틴(vincristine) 등이 있다.The chemotherapeutic agent means an organic compound that exhibits a pharmacological effect on any disease. Representative examples of such chemotherapeutic agents include anticancer chemotherapeutic agents. Known anticancer chemotherapeutic agents include, for example, paclitaxel, docetaxel, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, daunorubicin, Epirubicin, idarubicin, valubicin, mitoxantrone, curcumin, gefitinib, erlotinib, irinotecan , Topotecan, vinblastine, vincristine and the like.

상기 단백질 의약 또는 핵산의약은 예를 들어, 특정 수용체에 특이적으로 결합하여 신호 전달을 차단하거나 억제하는 펩타이드, 특정 유전자의 발현을 저해하는 siRNA 등이 이에 해당된다.The protein drug or nucleic acid drug may include, for example, peptides that specifically bind to specific receptors to block or inhibit signal transduction, and siRNAs that inhibit the expression of specific genes.

상기 핵산은 올리고 핵산을 포함한다. 보다 구체적으로 플라스미드 디옥시리보핵산(plasmid DNA), 리보핵산(RNA), 작은 간섭 리보핵산(siRNA), 안티센스 올리고핵산(antisense oligonucleotide), 마이크로 리보핵산 (microRNA), 잠금형 핵산 (locked nucleic acid), 또는 핵산 앱타머(aptamer) 등을 포함한다.The nucleic acid includes an oligo nucleic acid. More specifically plasmid deoxyribonucleic acid (ribbonidic acid), ribonucleic acid (RNA), small interfering ribonucleic acid (siRNA), antisense oligonucleotide, microribonucleic acid (microRNA), locked nucleic acid, or Nucleic acid aptamers and the like.

또한 본 발명의 약물 전달체의 양이온성 키토산 유도체는 예를 들어 하기 화학식 1 또는 화학식 2의 구조를 가지는 화합물을 포함한다. In addition, the cationic chitosan derivative of the drug carrier of the present invention includes, for example, a compound having a structure of Formula 1 or Formula 2.

[화학식 1][Formula 1]

Figure 112009026795293-pat00003
Figure 112009026795293-pat00003

[화학식 2][Formula 2]

Figure 112009026795293-pat00004
Figure 112009026795293-pat00004

상기 식에서 R은 지용성 비타민 또는 그 유도체로부터 유도된 유기기를 나타내고, Wherein R represents an organic group derived from a fat-soluble vitamin or a derivative thereof,

L은 -CONH- 또는 -NHCOO-을 나타내고,L represents -CONH- or -NHCOO-,

M은 -COO- 또는 -O(CH2)2O-를 나타내며, M represents -COO- or -O (CH 2 ) 2 O-,

X는 아세틸기, 메틸글리콜기, 갈락토실기, 락토실기 또는 말토실기를 나타내고,X represents an acetyl group, methyl glycol group, galactosyl group, lactosyl group or maltosyl group,

a 및 b는 각각 독립적으로 1내지 150의 정수를 나타내며, a and b each independently represent an integer of 1 to 150,

c는 0내지 50의 정수를 나타내고,c represents an integer of 0 to 50,

n은 1 내지 4의 정수를 나타낸다. n represents the integer of 1-4.

일 구체 예에서 상기 R은 레티놀(retinol), 9-시스-레티놀산(9-cis-retinoic acid), 13-시스-레티놀산(13-cis-retinoic acid), 올-트랜스-레티놀산(all-trans-retinoic acid), 에르고칼시페롤(ergocalciferol, vitamin D2), 비타민 D2 (6,19,19-d3)(Vitamin D2 (6,19,19-d3)), 콜레칼시페롤(cholecalciferol, vitamin D3), 비타민 D3 (6,19,19-d3)(vitamin D3 (6,19,19-d3)), (±)-알파-토코페롤((±)-α-tocopherol), (+)-알파-토코페롤((+)-α-tocopherol), (+)-베타-토코페롤((+)-β-tocopherol), 감마-토코페롤((+)-γ-tocopherol), 델타-토코페롤((+)-δ-tocopherol), 알파-토코페롤 숙시네이트(D-α-tocopherol succinate), 알파-토코페롤 폴리에틸렌글리콜(D-α-tocopherol polyethylene glycol), 알파-토코트리엔올(D-α-tocotrienol), (+)-베타-토코트리엔올((+)-β-tocotrienol), 델타-토코트리엔올(D-δ-tocotrienol), 및 감마-토코트리엔올(D-γ-tocotrienol)로 이루어진 그룹 중에서 선택된 비타민 또는 그 유도체로부터 유도된 유기기를 나타내나 이에 제한되지 않는다.In one embodiment the R is retinol, 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid (all -trans-retinoic acid), ergocalciferol (vitamin D2), vitamin D2 (6,19,19-d3) (Vitamin D2 (6,19,19-d3)), cholecalciferol, vitamin D3), vitamin D3 (6,19,19-d3) (vitamin D3 (6,19,19-d3)), (±) -alpha-tocopherol ((±) -α-tocopherol), (+)- Alpha-tocopherol ((+)-α-tocopherol), (+)-beta-tocopherol ((+)-β-tocopherol), gamma-tocopherol ((+)-γ-tocopherol), delta-tocopherol ((+) -δ-tocopherol), D-α-tocopherol succinate, D-α-tocopherol polyethylene glycol, D-α-tocotrienol, ( Group consisting of +)-beta-tocotrienol ((+)-β-tocotrienol), delta-tocotrienol (D-δ-tocotrienol), and gamma-tocotrienol (D-γ-tocotrienol) Vita selected from Or (b) it represents an organic group derived from a derivative thereof is not limited thereto.

다른 구체 예에서 상기 화학식 1 또는 화학식 2의 화합물은 c가 0인 화합물을 포함한다.In another embodiment, the compound of Formula 1 or Formula 2 includes a compound wherein c is 0.

또 다른 구체 예에서 상기 화학식 1 또는 화학식 2의 화합물은 c는 1내지 50이고, X는 갈락토실, 락토실 또는 말토실을 나타내는 화합물을 포함한다.In another embodiment, the compound of Formula 1 or Formula 2 includes a compound wherein c is 1 to 50 and X represents galactosyl, lactosyl or maltosyl.

또 다른 구체 예에서 상기 화학식 1 또는 화학식 2의 화합물은 In another embodiment the compound of Formula 1 or Formula 2 is

a와 b의 합이 2내지 50이고, the sum of a and b is 2 to 50,

R은 9-시스-레티놀산(9-cis-retinoic acid), 13-시스-레티놀산(13-cis- retinoic acid), 올-트랜스-레티놀산(all-trans-retinoic acid), (±)-알파-토코페롤((±)-α-tocopherol), 알파-토코페롤 숙시네이트(D-α-tocopherol succinate), (+)-알파-토코페롤((+)-α-tocopherol), 알파-토코페롤 폴리에틸렌글리콜(D-α-tocopherol polyethylene glycol), 및 알파-토코트리엔올(D-α-tocotrienol)로 이루어진 그룹 중에서 선택된 비타민 또는 그 유도체로부터 유도된 유기기를 나타내는 화합물을 포함한다.R is 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid, (±) -Alpha-tocopherol ((±) -α-tocopherol), alpha-tocopherol succinate, (+)-alpha-tocopherol ((+)-α-tocopherol), alpha-tocopherol polyethylene glycol (D-α-tocopherol polyethylene glycol), and alpha-tocotrienol (D-α-tocotrienol) includes a compound representing an organic group derived from a vitamin or a derivative thereof selected from the group consisting of.

본 발명에 따른 약물 전달체의 형태는 특별히 제한되지 않으나, 예를 들어 리포좀, 미셀, 에멀젼, 또는 나노입자의 제형을 가질 수 있다.The form of the drug carrier according to the present invention is not particularly limited, but may have, for example, a formulation of liposomes, micelles, emulsions, or nanoparticles.

본 발명은 또한The invention also

본 발명에 따른 약물 전달체; 및Drug delivery system according to the present invention; And

약제학적으로 허용 가능한 담체를 포함하는 의약 조성물에 관한 것이다. It relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

상기 약물 전달체는 종양, 관절염, 심혈관계, 내분비계 질환 등을 포함하는 병인성 단백질의 과다발현으로 야기되는 각종 질환들의 치료를 위해 세포 내로 도입될 수 있다. The drug carrier may be introduced into cells for the treatment of various diseases caused by overexpression of pathogenic proteins including tumors, arthritis, cardiovascular, endocrine diseases and the like.

본 발명의 약물 전달체는 핵산전달 효율이 우수할 뿐만 아니라 세포 독성이 낮으므로 병인성 단백질의 세포내 과다 발현을 억제하여 우수한 질환 치료 효과를 거둘 수 있다. Since the drug delivery system of the present invention not only has excellent nucleic acid delivery efficiency but also has low cytotoxicity, the drug delivery vehicle may have an excellent disease treatment effect by inhibiting intracellular overexpression of pathogenic proteins.

본 발명의 의약 조성물을 통해 in vivo 또는 ex vivo 상에서 세포 내부로 목적하는 약물을 도입하게 되면 표적 단백질의 발현을 선택적으로 감소시키거나 표적 유전자에 생긴 변이를 수정하는 역할을 하여 병인성 단백질의 과다 발현으로 발생되는 질환이나 표적 유전자로 인해 발생한 질환 등을 치료할 수 있게 된다. Introducing the desired drug into the cell in vivo or ex vivo through the pharmaceutical composition of the present invention selectively reduces the expression of the target protein or modifies the mutations in the target gene to overexpress the pathogenic protein. It is possible to treat diseases caused by the disease caused by the target gene or the like.

본 발명에 있어서, 상기 약물 전달체의 치료상 유효량은 질환 치료 효과를 기대하기 위하여 투여에 요구되는 양을 의미한다. 따라서, 질환의 종류, 질환의 중증도, 투여되는 핵산의 종류, 제형의 종류, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 치료 기간, 동시 사용되는 화학 항암제 등의 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 성인에게 상기 약물 전달체를 예컨대 1일 1회 투여시 0.001 mg/kg ~ 100 ㎎/kg의 용량으로 투여하는 것이 바람직하다. In the present invention, the therapeutically effective amount of the drug carrier means an amount required for administration in order to expect a disease therapeutic effect. Therefore, the type of disease, the severity of the disease, the type of nucleic acid to be administered, the type of formulation, the age, weight, general health, sex and diet of the patient, the time of administration, the route of administration and the duration of treatment, the chemotherapy drug used simultaneously, etc. It can be adjusted according to various factors including a drug. It is preferable to administer the drug carrier to an adult at a dose of 0.001 mg / kg to 100 mg / kg, for example, once daily.

본 발명에 따른 상기 조성물에 사용되는 담체는 의약 분야에서 통상 사용되는 담체 및 비히클을 포함하며, 구체적으로 이온 교환 수지, 알루미나, 알루미늄 스테아레이트, 레시틴, 혈청 단백질(예, 사람 혈청 알부민), 완충 물질(예, 여러 인산염, 글리신, 소르브산, 칼륨 소르베이트, 포화 식물성 지방산의 부분적인 글리세라이드 혼합물), 물, 염 또는 전해질(예, 프로타민 설페이트, 인산수소이나트륨, 인산수소캄륨, 염화나트륨 및 아연 염), 교질성 실리카, 마그네슘 트리실리케이트, 폴리비닐피롤리돈, 셀룰로즈계 기질, 폴리에틸렌 글리콜, 나트륨 카르복시메틸셀룰로즈, 폴리아릴레이트, 왁스, 폴리에틸렌 글리콜 또는 양모지 등을 포함하나 이에 제한되지 않는다. 본 발명의 조성물은 또한 상기 성분들 이외에 윤활제, 습윤제, 유화제, 현탁제, 또는 보존제 등을 추가로 포함할 수 있다.Carriers used in the composition according to the present invention include carriers and vehicles commonly used in the pharmaceutical field, and specifically, ion exchange resins, alumina, aluminum stearate, lecithin, serum proteins (eg, human serum albumin), buffer substances (E.g. various phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids), water, salts or electrolytes (e.g. protamine sulfate, disodium hydrogen phosphate, carbohydrogen phosphate, sodium chloride and zinc salts) , Colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose based substrates, polyethylene glycol, sodium carboxymethylcellulose, polyarylates, waxes, polyethylene glycols or wool, and the like. The compositions of the present invention may also further comprise lubricants, wetting agents, emulsifiers, suspending agents, preservatives and the like in addition to the above components.

본 발명의 약학제학적 조성물은 경구 투여용 제형 또는 주사제와 같은 비경 구 투여용 제형으로 제조할 수 있다.The pharmaceutical compositions of the present invention may be prepared in parenteral dosage forms such as oral dosage forms or injections.

경구 투여용 제형의 예로서는 정제, 트로치제, 로젠지, 수용성 또는 유성 현탁액, 조제분말 또는 과립, 에멀젼, 하드 또는 소프트 캡슐, 시럽 또는 엘릭시르제(elixirs)를 들 수 있다. 정제 및 캡슐 등의 제형으로 제제하기 위해서 락토오스, 사카로오스, 솔비톨, 마니톨, 전분, 아밀로펙틴, 셀룰로오스 또는 젤라틴과 같은 결합제, 디칼슘포스페이트와 같은 부형제, 옥수수 전분 또는 고구마 전분과 같은 붕괴제, 스테아르산 마그네슘, 스테아르산 칼슘, 스테아질 푸마르산 나트륨 또는 폴리에틸렌글리콜 왁스와 같은 윤활유가 함유될 수 있다. 또한 캡슐 제형의 경우에는 상기에서 언급한 물질 외에도 지방유와 같은 액체 담체를 함유할 수 있다. Examples of formulations for oral administration include tablets, troches, lozenges, water soluble or oily suspensions, prepared powders or granules, emulsions, hard or soft capsules, syrups or elixirs. For formulation into tablets and capsules, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, binders such as cellulose or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, magnesium stearate Lubricating oils, such as calcium stearate, sodium stea fumarate or polyethylene glycol wax. In addition, the capsule formulation may contain a liquid carrier such as fatty oil in addition to the above-mentioned substances.

경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제가 포함된다. 비수성용제, 현탁 용제는 프로필렌글리콜, 폴리에틸렌글리콜 또는 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. Formulations for oral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, and lyophilized preparations. Non-aqueous solvents and suspending solvents may be used vegetable oils such as propylene glycol, polyethylene glycol or olive oil, injectable esters such as ethyl oleate.

한 양태로서, 본 발명에 따른 조성물은 비경구 투여를 위한 수용성 용액으로 제조할 수 있다. 바람직하게는 한스 용액(Hank's solution), 링거 용액(Ringer's solution) 또는 물리적으로 완충된 염수와 같은 완충 용액을 사용할 수 있다. 수용성 주입(injection) 현탁액은 소디움 카르복시메틸셀룰로즈, 솔비톨 또는 덱스트란과 같이 현탁액의 점도를 증가시킬 수 있는 기질을 첨가할 수 있다.In one embodiment, the composition according to the invention may be prepared in an aqueous solution for parenteral administration. Preferably, buffer solutions such as Hanks' solution, Ringer's solution, or physically buffered saline may be used. Aqueous injection suspensions can be added with a substrate that can increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran.

본 발명의 조성물의 다른 바람직한 양태는 수성 또는 유성 현탁액의 멸균 주사용 제제의 형태일 수 있다. 이러한 현탁액은 적합한 분산제 또는 습윤제(예를 들 면 트윈 80) 및 현탁화제를 사용하여 본 분야에 공지된 기술에 따라 제형화할 수 있다. 멸균 주사용 제제는 또한 무독성의 비경구적으로 허용되는 희석제 또는 용매 중의 멸균 주사 용액 또는 현탁액(예를 들면 1,3-부탄디올 중의 용액)일 수 있다. 사용될 수 있는 비히클 및 용매로는 만니톨, 물, 링거 용액 및 등장성 염화나트륨 용액이 있다. 또한, 멸균 비휘발성 오일이 통상적으로 용매 또는 현탁화 매질로서 사용된다. 이러한 목적을 위해 합성 모노 또는 디글리세라이드를 포함하여 자극성이 적은 비휘발성 오일은 그 어느 것도 사용할 수 있다.Another preferred embodiment of the compositions of the present invention may be in the form of sterile injectable preparations of aqueous or oily suspensions. Such suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents (eg Tween 80) and suspending agents. Sterile injectable preparations may also be sterile injectable solutions or suspensions (eg solutions in 1,3-butanediol) in nontoxic parenterally acceptable diluents or solvents. Vehicles and solvents that may be used include mannitol, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, nonvolatile oils are conventionally employed as a solvent or suspending medium. For this purpose any non-irritating non-volatile oil can be used including synthetic mono or diglycerides.

본 발명은 또한 기재;The invention is also described;

상기 기재 상에 코팅된 본 발명에 따른 양이온성 키토산 유도체; 및Cationic chitosan derivatives according to the invention coated on the substrate; And

상기 양이온성 키토산 유도체와 결합된 핵산 앱타머를 포함하는 진단 키트에 관한 것이다.It relates to a diagnostic kit comprising a nucleic acid aptamer bound to the cationic chitosan derivative.

예를 들면 진단용 플레이트의 표면(기재)를 지용성 비타민 및 그 유도체 비타민들을 수식한 신규한 양이온성 키토산으로 코팅하고 이 코팅 면 위에 앱타머를 결합시킬 경우 시료 중 앱타머와 선택적으로 반응하는 물질의 존재를 진단하는데 이용 가능하다. For example, the surface (substrate) of the diagnostic plate is coated with a novel cationic chitosan modified with fat-soluble vitamins and derivative vitamins and the presence of a substance that selectively reacts with the aptamer in the sample when the aptamer is bound on the coated surface. It can be used to diagnose.

상술한 바와 같이, 본 발명의 지용성 비타민 및 그 유도체 비타민들을 수식한 신규한 양이온성 키토산 유도체는 제조 및 정제 공정이 간편하여 대량 생산시의 경제성이 높다. 또한, 본 발명의 지용성 비타민 및 그 유도체 비타민들을 수식한 신규한 양이온성 키토산을 포함하는 약물 전달체는 목적하는 약제학적 활성성분, 예를 들어 리보핵산, 작은 간섭 리보핵산, 안티센스 올리고핵산, 핵산 앱타머 (aptamer) 등의 올리고 핵산 의약을 세포 내로 수송하는 효율을 현저히 증강시킬 뿐만 아니라, 세포 독성을 감소시켜 핵산 또는 단백질 소재 의약의 치료 효능을 증강시키는 용도로 유용하게 사용된다. As described above, the novel cationic chitosan derivatives modified with the fat-soluble vitamins of the present invention and the derivative vitamins thereof are simple to manufacture and purify, and thus economical in mass production. In addition, a drug delivery agent comprising a novel cationic chitosan modified from fat-soluble vitamins and derivative vitamins of the present invention may be used as a pharmaceutical active ingredient of interest, for example ribonucleic acid, small interfering ribonucleic acid, antisense oligonucleic acid, nucleic acid aptamers. In addition to significantly enhancing the efficiency of transporting oligonucleic acid drugs such as aptamers into cells, they are usefully used for enhancing the therapeutic efficacy of nucleic acid or protein based drugs by reducing cytotoxicity.

본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다. Advantages and features of the present invention and methods for achieving them will be apparent with reference to the embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in various forms, and only the embodiments are intended to complete the disclosure of the present invention, and the general knowledge in the technical field to which the present invention pertains. It is provided to fully convey the scope of the invention to those skilled in the art, and the present invention is defined only by the scope of the claims.

하기 실시 예에서는 상기 핵산 전달체의 종양세포(사람의 자궁경부암 상피 세포인 HeLa 세포주, 케라틴 분비형 자궁경부암 세포 KB 세포주, 폐암 세포인 A549 세포주, 흑색종인 WM266.4 세포주, 백혈병 세포인 K562세포주와 TF-1 세포주, 쥐의 간암 세포주인 Hepa 1-6 세포주)로의 핵산 전달 효율을 평가하였다. In the following examples, the tumor cells of the nucleic acid carrier (HeLa cell line, which is a human cervical cancer epithelial cell, KB type keratin-secreting cervical cancer cell, A549 cell line, which is a lung cancer cell, WM266.4 cell line, which are melanoma, and K562 cell line, which are leukemia cells, and TF) The efficiency of nucleic acid delivery to -1 cell line, Hepa 1-6 cell line, a rat liver cancer cell line) was evaluated.

형광 표식이 붙어있는 Block IT (Invitrogen, USA) 작은 간섭 리보핵산을 사 용하여 지용성 비타민 및 그 유도체 비타민들을 수식한 신규한 양이온성 올리고 키토산을 함유하는 다양한 복합체를 형성시켜 세포 내에 전달하고 이를 형광 현미경으로 관찰하면 상기 지용성 비타민 및 그 유도체 비타민들을 수식한 신규한 양이온성 키토산의 세포 내로 전달되는 핵산 수송 능력을 구체적으로 측정하였다. Block IT with fluorescent labeling (Invitrogen, USA) Using a small interfering ribonucleic acid, a variety of complexes containing novel cationic oligochitosans modified with fat-soluble vitamins and their derivative vitamins are formed and delivered into cells and fluorescence microscope Observation was specifically measured the capacity of the nucleic acid transport to the cells of the novel cationic chitosan modified by the fat-soluble vitamin and its derivative vitamins.

또한 본 발명의 핵산 전달체의 세포 독성은 tetrazolium 3-(4,5-dimethylthiazol -2-yl)-2,5-diphenyltetrazolium bromide을 이용한 발색 방법 (MTT)을 사용하여 평가하였다. In addition, the cytotoxicity of the nucleic acid carrier of the present invention was evaluated using the color development method (MTT) using tetrazolium 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide.

[신규 키토산 유도체의 합성] [Synthesis of New Chitosan Derivatives]

비교예 1. 기존에 판매되고 있는 양이온성 리포좀 Comparative Example 1. Cationic Liposomes

기존의 핵산 전달 실험용으로 시판되고 있는 리포좀 제형인 리포펙타민(LipofectAMINE)TM 2000(Invitrogen, USA)을 구입하여 사용하였으며, 제조사의 지침을 따라서 수행하였다. Lipofectamine (LipofectAMINE) 2000 (Invitrogen, USA), a commercially available liposome formulation for use in nucleic acid delivery experiments, was purchased and used according to the manufacturer's instructions.

<실시예><Example>

실시예 1. 레티닐 키토산 유도체 (Retinyl chitosan derivatives)의 합성 Example 1 Synthesis of Retinyl chitosan derivatives

분자량 1kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 레티놀(retinol, 0.017g, sigma, USA)을 첨가한 후 80℃에서 12시간 정도 교반하였다. 반응 후 얻어진 생성물을 미반응 물질과 불순물을 제거하기 위해 투석막을 사용하여 물에서 투석한 후 동결 건조하였다. 얻어진 키토산 유도체는 사용하기 전까지 4℃에서 보관하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 1kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), retinol (retinol, 0.017 g, sigma, USA), and then added at 12 Stir for about hour. The product obtained after the reaction was dialyzed in water using a dialysis membrane to remove unreacted material and impurities, and then freeze-dried. The obtained chitosan derivative was stored at 4 ° C. until use. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 2. 레티닐 키토산 유도체 (Retinyl chitosan derivatives)의 합성 Example 2 Synthesis of Retinyl chitosan derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 레티놀(retinol, 0.17g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA) and retinol (retinol, 0.17 g, sigma, USA) were added after Example 1 and Chitosan derivatives were synthesized in the same manner. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 3. 레티닐 키토산 유도체 (Retinyl chitosan derivatives)의 합성 Example 3 Synthesis of Retinyl chitosan derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과CDI(1,1'- Carbonyldiimidazole, 0.1g, sigma-aldrich, USA), 레티놀(retinol, 0.52g, sigma, USA)을 첨가한 후 12시간 정도 교반하였다. 반응 후 얻어진 생성물을 미반응 물질과 불순물을 제거하기 위해 투석막을 사용하여 물에서 투석한 후 동결 건조하였다. 얻어진 키토산 유도체는 사용하기 전까지 4℃에서 보관하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. After dissolving 50 kDa chitosan (chitosan, 1g, aldrich, USA) in DMF / H2O = 95/5, DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and CDI (1,1'-Carbonyldiimidazole, 0.1) g, sigma-aldrich, USA) and retinol (retinol, 0.52g, sigma, USA) were added and stirred for about 12 hours. The product obtained after the reaction was dialyzed in water using a dialysis membrane to remove unreacted material and impurities, and then freeze-dried. The obtained chitosan derivative was stored at 4 ° C. until use. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 4. 레티노일 키토산 유도체 (Retinoyl chitosan derivatives)의 합성 Example 4 Synthesis of Retinoyl chitosan derivatives

분자량 1kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 레티놀산(retinoic acid, 0.54g, sigma, USA)을 첨가한 후 상온에서 12시간정도 교반하였다. 반응 후 얻어진 생성물을 미반응 물질과 불순물을 제거하기 위해 투석막을 사용하여 물에서 투석한 후 동결 건조하였다. 얻어진 키토산 유도체는 사용하기 전까지 4℃에서 보관하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. NMR 그래프를 도 1에 도시하였다.Molecular weight 1kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and retinoic acid (retinoic acid, 0.54 g, sigma, USA) were added and stirred at room temperature for 12 hours. The product obtained after the reaction was dialyzed in water using a dialysis membrane to remove unreacted material and impurities, and then freeze-dried. The obtained chitosan derivative was stored at 4 ° C. until use. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA). NMR graphs are shown in FIG. 1.

1H NMR of retinoyl chitosan(500 MHz, D2O): 1.2 ppm (CH 3 from retinoic acid); 1.3-1.5 ppm (CH 2 from retinoic acid); 1.7-2.2 ppm (CH 3 from retinoic acid); 2.9 ppm (CH 3 from retinoic acid); 6.8 ppm (H from retinoic acid); 1.9 ppm CH 3CO from chitosan); 3.0-4.3 ppm (CH from chitosan); 4.7 ppm (OH from chitosan); 5.2-5.4 ppm (CH from chitosan); 8.0 ppm (CONH from retinoyl chitosan). 1 H NMR of retinoyl chitosan (500 MHz, D 2 O): 1.2 ppm (C H 3 from retinoic acid); 1.3-1.5 ppm (C H 2 from retinoic acid); 1.7-2.2 ppm (C H 3 from retinoic acid); 2.9 ppm (C H 3 from retinoic acid); 6.8 ppm ( H from retinoic acid); 1.9 ppm C H 3 CO from chitosan); 3.0-4.3 ppm (C H from chitosan); 4.7 ppm (O H from chitosan); 5.2-5.4 ppm (C H from chitosan); 8.0 ppm (CON H from retinoyl chitosan).

실시예 5. 레티노일 키토산 유도체 (Retinoyl chitosan derivatives)의 합성 에스터 Example 5 Synthetic Ester of Retinoyl chitosan Derivatives

Figure 112009026795293-pat00005
Figure 112009026795293-pat00005

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)과 과량의 무수프탈산(excess phthalic anhydride)을 DMF/H2O=95/5에 녹인 후 120℃에서 약 8시간정도 교반하였다. 반응 종료 후 미반응 물질을 제거하기 위해 얼음물을 부어 침전시킨 후 메탄올(methanol)로 씻어준다. 얻어진 물질에 레티놀산(retinoic aicd, 0.18g, sigma, USA), DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)을 첨가한 후 80℃에서 12시간정도 교반하였다. 반응 종료 후 100℃에서 하이드라진 (hydrazine hydrate)첨가하여 보호기를 제거한다. 반응 후 얻어진 생성물을 미반응 물질과 불순물을 제거하기 위해 투석막을 사용하여 물에서 투석한 후 동결 건조하였다. 얻어진 키토산 유도체는 사용하기 전까지 4℃에서 보관하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) and excess phthalic anhydride were dissolved in DMF / H 2 O = 95/5 and stirred at 120 ° C. for about 8 hours. After completion of the reaction, to remove the unreacted material, pour iced water to precipitate and wash with methanol. Retinoic acid (retinoic aicd, 0.18g, sigma, USA) and DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) were added to the obtained material, followed by stirring at 80 ° C for about 12 hours. After completion of the reaction, the hydrazine (hydrazine hydrate) is added at 100 ℃ to remove the protecting group. The product obtained after the reaction was dialyzed in water using a dialysis membrane to remove unreacted material and impurities, and then freeze-dried. The obtained chitosan derivative was stored at 4 ° C. until use. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 6. 콜레칼시페릴 키토산 유도체 (Cholecalciferyl chitosan derivatives)의 합성 Example 6 Synthesis of Cholecalciferyl chitosan Derivatives

분자량 1kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 콜레칼시페롤(cholecalciferol, 0.69g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 1kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), cholecalciferol (0.69 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 7. 콜레칼시페릴 키토산 유도체 (Cholecalciferyl chitosan derivatives)의 합성 Example 7 Synthesis of Cholecalciferyl chitosan Derivatives

분자량 10kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 콜레칼시페롤(cholecalciferol, 0.077g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 10kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), cholecalciferol (0.077 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 8. 콜레칼시페릴 키토산 유도체 (Cholecalciferyl chitosan derivatives)의 합성 Example 8 Synthesis of Cholecalciferyl chitosan Derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과CDI(1,1'-Carbonyldiimidazole, 0.1g, sigma-aldrich, USA), 콜레칼시페롤(cholecalciferol, 0.014g, sigma, USA)을 첨가한 후 실시예 3과 동일한 방법으로 키토산 유도체를 합 성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and CDI (1,1'-Carbonyldiimidazole, 0.1 g, sigma-aldrich, USA), cholecalciferol (cholecalciferol, 0.014g, sigma, USA) was added, and then chitosan derivatives were synthesized in the same manner as in Example 3. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 9. 알파-토코페릴 키토산 유도체 (α-Tocopherol formylbenzoyl chitosan derivatives)의 합성 Example 9 Synthesis of α-Tocopherol formylbenzoyl chitosan derivatives

알파-토코페롤(α-tocopherol, 100mg, sigma, USA)을 DMF에 녹인 후, DMAP(4-(Dimethylamino)pyridine, 0.01g, Fluka, USA), SFB(succinimidyl 4-formylbenzoate, 0.086, Fisher Scientific Inc., USA)를 첨가한 후, 60℃에서 12시간정도 반응시켰다. 반응 후 감압농축하고 에틸아세테이트(Ethyl acetate), 과포화 염화나트륨 수용액으로 씻어준 후 건조시켰다. 분자량 10kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), 얻어진 중간유도체인 알파-토코페롤 포밀벤조산(α-tocopherol formylbenzoate, 0.026g)을 첨가한 후 상온에서12시간동안 교반하여 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Alpha-tocopherol (α-tocopherol, 100 mg, sigma, USA) was dissolved in DMF, followed by DMAP (4- (Dimethylamino) pyridine, 0.01 g, Fluka, USA), SFB (succinimidyl 4-formylbenzoate, 0.086, Fisher Scientific Inc. , USA) was added and then reacted at 60 ° C for about 12 hours. After the reaction was concentrated under reduced pressure, washed with ethyl acetate (Ethyl acetate), an aqueous supersaturated sodium chloride solution and dried. After dissolving 10 kDa chitosan (chitosan, 1g, aldrich, USA) in DMF / H2O = 95/5, DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), the intermediate derivative alpha-tocopherol formylbenzoic acid ( α-tocopherol formylbenzoate (0.026g) was added and stirred for 12 hours at room temperature to synthesize chitosan derivatives. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 10. 알파-토코페릴 키토산 유도체 (α-Tocopherol formylbenzoyl chitosan derivatives)의 합성 Example 10 Synthesis of α-Tocopherol Formylbenzoyl Chitosan Derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)에 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), 실시예 9와 같이 합성한 알파-토코페롤 포밀벤조산(α-tocopherol formylbenzoate, 0.47g)을 첨가한 후 실시예 9와 동일한 방법으로 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Alpha-tocopherol synthesized as DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), Example 9 after dissolving in DMF / H2O = 95/5 in molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) Formyl benzoic acid (α-tocopherol formylbenzoate, 0.47g) was added and then synthesized in the same manner as in Example 9. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 11. 감마-토코페릴 키토산 유도체 (γ-Tocopheryl chitosan derivatives)의 합성 Example 11.Synthesis of Gamma-Tocopheryl chitosan derivatives

분자량 1kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 감마-토코페롤(γ-tocopherol, 0.78g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 1kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), gamma-tocopherol (γ-tocopherol, 0.78 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 12. 감마-토코페릴 키토산 유도체 (γ-Tocopheryl chitosan derivatives)의 합성 Example 12 Synthesis of Gamma-Tocopheryl chitosan Derivatives

분자량 10kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과CDI(1,1'-Carbonyldiimidazole, 0.1g, sigma-aldrich, USA), 감마-토코페롤(γ-tocopherol, 0.026g, sigma, USA)을 첨가한 후 실시예 3과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Dissolve molecular weight 10kDa chitosan (chitosan, 1g, aldrich, USA) in DMF / H2O = 95 /, then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and CDI (1,1'-Carbonyldiimidazole, 0.1g , sigma-aldrich, USA) and gamma-tocopherol (γ-tocopherol, 0.026 g, sigma, USA) were added, and then chitosan derivatives were synthesized in the same manner as in Example 3. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 13. 감마-토코페릴 키토산 유도체 (γ-Tocopheryl chitosan derivatives)의 합성 Example 13. Synthesis of γ-Tocopheryl chitosan derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 감마-토코페롤(γ-tocopherol, 0.26g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), gamma-tocopherol (γ-tocopherol, 0.26 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 14. 델타-토코페릴 키토산 유도체 (δ-Tocopheryl chitosan derivatives)의 합성 Example 14 Synthesis of delta-tocopheryl chitosan derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 감마-토코페롤(δ-tocopherol, 0.78g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95 /, then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) -N '-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), gamma-tocopherol (δ-tocopherol, 0.78 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 15. 델타-토코페릴 키토산 유도체 (δ-Tocopheryl chitosan derivatives)의 합성 Example 15 Synthesis of delta-tocopheryl chitosan derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 델타-토코페롤(δ-tocopherol, 0.026g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), delta-tocopherol (δ-tocopherol, 0.026 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 16. 알파-토코트리엔오일 키토산 유도체 (α-Tocotrienoyl chitosan derivatives)의 합성 Example 16 Synthesis of α-Tocotrienoyl chitosan derivatives

분자량 1kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 알파-토코트리엔올(α-tocotrienol, 0.75g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 1kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA) and alpha-tocotrienol (α-tocotrienol, 0.75 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1 after the addition. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 17. 알파-토코트리엔오일 키토산 유도체 (α-Tocotrienoyl chitosan derivatives)의 합성 Example 17 Synthesis of α-Tocotrienoyl chitosan derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과CDI(1,1'-Carbonyldiimidazole, 0.1g, sigma-aldrich, USA), 알파-토코트리엔올(α-tocotrienol, 0.025g, sigma, USA)을 첨가한 후 실시예 3과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and CDI (1,1'-Carbonyldiimidazole, 0.1 g, sigma-aldrich, USA) and alpha-tocotrienol (α-tocotrienol, 0.025 g, sigma, USA) were added, and then a chitosan derivative was synthesized in the same manner as in Example 3. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 18. 감마-토코트리엔오일 키토산 유도체 (γ-Tocotrienoyl chitosan derivatives)의 합성 Example 18 Synthesis of Gamma-Tocotrienoyl chitosan Derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydridee, 0.1g, sigma-aldrich, USA), 감마-토코트리엔올(γ-tocotrienol, 0.74g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydridee (0.1 g, sigma-aldrich, USA), gamma-tocotrienol (γ-tocotrienol, 0.74 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1 after the addition. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 19. 감마-토코트리엔오일 키토산 유도체 (γ-Tocotrienoyl chitosan derivatives)의 합성 Example 19 Synthesis of Gamma-Tocotrienoyl chitosan Derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 감마-토코트리엔올(γ- tocotrienol, 0.25g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), gamma-tocotrienol (γ- tocotrienol, 0.25 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1 after the addition. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 20. 델타-토코트리엔오일 키토산 유도체 (δ-Tocotrienoyl chitosan derivatives)의 합성 Example 20 Synthesis of Delta-Tocotrienoyl chitosan Derivatives

분자량 10kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 델타-토코트리엔올(δ-tocotrienol, 0.025g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 10kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), delta-tocotrienol (δ-tocotrienol, 0.025 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1 after the addition. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 21. 델타-토코트리엔오일 키토산 유도체 (δ-Tocotrienoyl chitosan derivatives)의 합성 Example 21.Synthesis of delta-tocotrienoyl chitosan derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2- dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 델타-토코트리엔올(δ-tocotrienol, 0.25g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), delta-tocotrienol (δ-tocotrienol, 0.25 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1 after the addition. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 22. 에르고칼시페릴 키토산 유도체 (Ergocalciferyl chitosan derivatives)의 합성 Example 22 Synthesis of Ergocalciferyl chitosan Derivatives

분자량 10kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 에르고칼시페롤(ergocalciferol, 0.24g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 10kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA) and ergocalciferol (ergocalciferol, 0.24 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 23. 에르고칼시페릴 키토산 유도체 (Ergocalciferyl chitosan derivatives)의 합성 Example 23 Synthesis of Ergocalciferyl chitosan derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 에르고칼시페롤(ergocalciferol, 0.72g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), succinic anhydride (0.1g, sigma-aldrich, USA) and ergocalciferol (ergocalciferol, 0.72g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 24. 알파-토코페릴 키토산 유도체 (α-Tocopheryl chitosan derivatives)의 합성 Example 24. Synthesis of α-Tocopheryl chitosan derivatives

Figure 112009026795293-pat00006
Figure 112009026795293-pat00006

분자량 10kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 알파-토코페롤 숙시네이트(α-tocopherol succinate, 0.032g, supelco, USA)를 첨가한 후 실시예 4와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하고 이를 도 2에 도시하였다. After dissolving 10 kDa chitosan (chitosan, 1g, aldrich, USA) in DMF / H2O = 95/5, DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and alpha-tocopherol succinate (α-tocopherol succinate, 0.032 g, supelco, USA) were added, and then the chitosan derivative was synthesized in the same manner as in Example 4. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA) and this is shown in FIG. Shown.

실시예 25. 알파-토코페릴 키토산 유도체 (α-Tocopheryl chitosan derivatives)의 합성 Example 25 Synthesis of α-Tocopheryl chitosan derivatives

분자량 50kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 알파-토코페롤 숙시네이트(α-tocopherol succinate, 0.32g, supelco, USA)를 첨가한 후 실시예 4와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Dissolve molecular weight 50kDa chitosan (chitosan, 1g, aldrich, USA) in DMF / H2O = 95/5, then DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and alpha-tocopherol succinate (α-tocopherol succinate, 0.32 g, supelco, USA) were added, and then a chitosan derivative was synthesized in the same manner as in Example 4. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 26. 알파-토코페릴 키토산 유도체 (α-Tocopheryl chitosan derivatives)의 합성 아미드 Example 26 Synthetic Amides of α-Tocopheryl Chitosan Derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 알파-토코페롤 숙시네이트(α-tocopherol succinate, 0.32g, supelco, USA)을 첨가한 후 실시예 4와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 30kDa chitosan (chitosan, 1g, aldrich, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and alpha-tocopherol succinate (α-tocopherol succinate, 0.32 g, supelco, USA) were added, and then a chitosan derivative was synthesized in the same manner as in Example 4. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 27. 토코페롤 폴리에틸렌글리콜릭 키토산 유도체 (Tocopherol polyethylene glycolic chitosan derivatives)의 합성 Example 27 Synthesis of Tocopherol Polyethylene Glycol Chitosan Derivatives

분자량 1kDa 키토산(chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과 CDI(1,1'-Carbonyldiimidazole, 0.1g, sigma-aldrich, USA), 알파 토코페롤 폴리에틸렌글리콜(α-tocopherol polyethylene glycol, 0.69g, sigma, USA)을 첨가한 후 실시예 3과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Molecular weight 1kDa chitosan (chitosan, 1g, sigma, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA) and CDI (1,1'-Carbonyldiimidazole, 0.1 g, sigma-aldrich, USA) and alpha tocopherol polyethylene glycol (α-tocopherol polyethylene glycol, 0.69 g, sigma, USA) were added, and then the chitosan derivative was synthesized in the same manner as in Example 3. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 28. 토코페롤 폴리에틸렌글리콜릭 키토산 유도체 (Tocopherol polyethylene glycolic chitosan derivatives)의 합성 Example 28 Synthesis of Tocopherol Polyethylene Glycol Chitosan Derivatives

분자량 30kDa 키토산(chitosan, 1g, aldrich, USA)을 실시예 5와 동일한 방법으로 합성한 물질에 알파 토코페롤 폴리에틸렌글리콜(α-tocopherol polyethylene glycol, 0.32g, supelco, USA), DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA)를 첨가한 후 실시예 5와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. To a material synthesized with a molecular weight of 30 kDa chitosan (chitosan, 1 g, aldrich, USA) in the same manner as in Example 5, alpha-tocopherol polyethylene glycol (0.32 g, supelco, USA), DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA) After adding the chitosan derivative was synthesized in the same manner as in Example 5. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 29. 레티노일 메틸글리콜 키토산 유도체 (Retinoyl methylglycol chitosan derivatives)의 합성 Example 29. Synthesis of Retinoyl methylglycol chitosan derivatives

메틸글리콜 키토산(methylglycol chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 레티놀산(retinoic aicd, 0.018g, sigma, USA)을 첨가한 후 실시예 4와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) 및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Methylglycol chitosan (1g, sigma, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and retinoic acid (retinoic aicd, 0.018 g, sigma, USA) were added, and then chitosan derivatives were synthesized in the same manner as in Example 4. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 30. 콜레칼시페릴 갈락토실 키토산 유도체 (Cholecalciferyl galactosyl chitosan derivatives)의 합성 Example 30 Synthesis of Cholecalciferyl galactosyl chitosan derivatives

갈락토실 키토산(galactosyl chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 콜레칼시페롤(cholecalciferol, 0.077g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Galactosyl chitosan (1 g, sigma, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) ) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) plus succinic anhydride (0.1 g, sigma-aldrich, USA), cholecalciferol (0.077 g, sigma, USA) After the chitosan derivative was synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 31. 델타-토코트리엔오일 갈락토실 키토산 유도체 (δ-Tocotrienoyl galactosyl chitosan derivatives)의 합성 Example 31.Synthesis of delta-tocotrienoyl galactosyl chitosan derivatives

갈락토실 키토산(galactosyl chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙 신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 델타-토코트리엔올(δ-tocotrienol, 0.25g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Galactosyl chitosan (1 g, sigma, USA) was dissolved in DMF / H2O = 95/5 and then DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) ) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and succinic anhydride (0.1 g, sigma-aldrich, USA), delta-tocotrienol (δ-tocotrienol, 0.25 g, sigma, USA) and then the chitosan derivative was synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 32. 알파-토코페릴 갈락토실 키토산 유도체 (α-Tocopheryl galactosyl chitosan derivatives)의 합성 Example 32. Synthesis of alpha-tocopheryl galactosyl chitosan derivatives

갈락토실 키토산(galactosyl chitosan, 1g, sigma, USA)을 실시예 5와 동일한 방법으로 합성한 물질에 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), 알파-토코페롤 숙시네이트(α-tocopherol succinate, 0.032g, supelco, USA)를 첨가한 후 12시간정도 교반한 후 실시예 5와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Galactosyl chitosan (1 g, sigma, USA) was synthesized in the same manner as in Example 5 DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), alpha-tocopherol succinate (α) -tocopherol succinate, 0.032g, supelco, USA) and after stirring for about 12 hours to synthesize a chitosan derivative in the same manner as in Example 5. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 33. 레티닐 락토실 키토산 유도체 (Retinyl lactosyl chitosan derivatives)의 합성 Example 33. Synthesis of Retinyl lactosyl chitosan derivatives

락토실 키토산(lactosyl chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), CDI(1,1'- Carbonyldiimidazole, 0.1g, sigma-aldrich, USA), 레티놀(retinol, 0.017g, sigma, USA)을 첨가한 후 실시예 3과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다.　 After lactosyl chitosan (1g, sigma, USA) was dissolved in DMF / H2O = 95/5, DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), CDI (1,1'-Carbonyldiimidazole, Chitosan derivatives were synthesized in the same manner as in Example 3 after adding 0.1 g, sigma-aldrich, USA) and retinol (retinol, 0.017 g, sigma, USA). The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 34. 에르고칼시페릴 락토실 키토산 유도체 (Ergocalciferyl lactosyl chitosan derivatives)의 합성Example 34 Synthesis of Ergocalciferyl lactosyl chitosan derivatives

Figure 112009026795293-pat00007
Figure 112009026795293-pat00007

락토실 키토산(lactosyl chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 에르고칼시페 롤(ergocalciferol, 0.24g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. After lactosyl chitosan (1g, sigma, USA) was dissolved in DMF / H2O = 95/5, DMAP (4- (Dimethylamino) pyridine, 0.1g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) plus succinic anhydride (0.1 g, sigma-aldrich, USA) and ergocalciferol (ergocalciferol, 0.24 g, sigma, USA) After the chitosan derivative was synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 35. 알파-토코페릴 락토실 키토산 유도체 (α-Tocopheryl lactosyl chitosan derivatives)의 합성 Example 35. Synthesis of alpha-tocopheryl lactosyl chitosan derivatives

락토실 키토산(lactosyl chitosan, 1g, sigma, USA)을 실시예 5와 동일한 방법으로 합성한 물질에 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 알파-토코페롤 숙시네이트(α-tocopherol succinate, 0.96g, supelco, USA)를 첨가한 후 상온에서 12시간정도 교반한 후 실시예 5와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Lactose chitosan (lactosyl chitosan, 1 g, sigma, USA) was synthesized in the same manner as in Example 5 DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl) ) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), alpha-tocopherol succinate (α-tocopherol succinate, 0.96 g, supelco, USA) and then stirred at room temperature for about 12 hours, Example 5 Chitosan derivatives were synthesized in the same manner as. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 36. 감마-토코트리엔오일 말토실 키토산 유도체 (γ-Tocotrienoyl maltosyl chitosan derivatives)의 합성 Example 36 Synthesis of Gamma-Tocotrienoyl Maltosyl Chitosan Derivatives

말토실 키토산(maltosyl chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2- dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 감마-토코트리엔올(γ-tocotrienol, 0.025g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Maltosyl chitosan (1 g, sigma, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and succinic anhydride, 0.1 g, sigma-aldrich, USA, gamma-tocotrienol (0.025 g, sigma, USA) After the addition of the chitosan derivative was synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 37. 레티노일 말토실 키토산 유도체 (Retinoyl maltosyl chitosan derivatives)의 합성 Example 37.Synthesis of Retinoyl maltosyl chitosan derivatives

말토실 키토산(maltosyl chitosan, 1g, sigma, USA)을 실시예 5와 동일한 방법으로 합성한 물질에 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 레티놀산(retinoic acid, 0.54g, sigma, USA)을 첨가한 후 실시예 5와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Maltosyl chitosan (1 g, sigma, USA) was synthesized in the same manner as in Example 5 with DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl). ) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and retinoic acid (retinoic acid, 0.54 g, sigma, USA) were added, and then a chitosan derivative was synthesized in the same manner as in Example 5. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 38. 에르고칼시페릴 글리콜 키토산 유도체 (Ergocalciferyl glycol chitosan derivatives)의 합성 Example 38 Synthesis of Ergocalciferyl glycol chitosan derivatives

글리콜 키토산(glycol chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), CDI(1,1'-Carbonyldiimidazole, 0.1g, sigma-aldrich, USA)와 에르고칼시페롤(ergocalciferol, 0.72g, sigma, USA)을 첨가한 후 실시예 3과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다.　 Glycol chitosan (1 g, sigma, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), CDI (1,1'-Carbonyldiimidazole, 0.1 g, sigma-aldrich, USA) and ergocalciferol (ergocalciferol, 0.72 g, sigma, USA) were added, and then chitosan derivatives were synthesized in the same manner as in Example 3. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 39. 델타-토코페릴 글리콜 키토산 유도체 (δ-Tocopheryl glycol chitosan derivatives)의 합성 Example 39. Synthesis of delta-tocopheryl glycol chitosan derivatives

글리콜 키토산(glycol chitosan, 1g, sigma, USA)을 DMF/H2O=95/5에 녹인 후 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA), EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA)와 무수숙신산(succinic anhydride, 0.1g, sigma-aldrich, USA), 델타-토코페롤(δ-tocopherol, 0.026g, sigma, USA)을 첨가한 후 실시예 1과 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Glycol chitosan (1 g, sigma, USA) was dissolved in DMF / H2O = 95/5, followed by DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA), EDC (N- (2-dimethylaminopropyl)- N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA), succinic anhydride (0.1 g, sigma-aldrich, USA), delta-tocopherol (δ-tocopherol, 0.026 g, sigma, USA) Chitosan derivatives were synthesized in the same manner as in Example 1. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

실시예 40. 레티노일 글리콜 키토산 유도체 (Retinoyl glycol chitosan derivatives)의 합성 Example 40 Synthesis of Retinoyl glycol chitosan derivatives

글리콜 키토산(glycol chitosan, 1g, sigma, USA)을 실시예 5와 동일한 방법으로 합성한 물질에 DMAP(4-(Dimethylamino)pyridine, 0.1g, Fluka, USA)과 EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide, 0.1g, sigma-aldrich, USA), 레티놀산(retinoic aicd, 0.018g, sigma, USA)을 첨가한 후 실시예 5와 동일한 방법으로 키토산 유도체를 합성하였다. 반응 여부는 핵자기공명법 (NMR, Nuclear Magnetic Resonance, varian, Inc., USA)및 적외선 흡수 스펙트럼 분석법(FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA)으로 확인하였다. Glycol chitosan (1 g, sigma, USA) was synthesized in the same manner as in Example 5 DMAP (4- (Dimethylamino) pyridine, 0.1 g, Fluka, USA) and EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide, 0.1 g, sigma-aldrich, USA) and retinoic acid (retinoic aicd, 0.018 g, sigma, USA) were added, and then chitosan derivatives were synthesized in the same manner as in Example 5. The reaction was confirmed by nuclear magnetic resonance (NMR, Nuclear Magnetic Resonance, varian, Inc., USA) and infrared absorption spectroscopy (FT-IR, Infrared absorption spectroscopy, Thermo Fisher Scientific Inc., USA).

<실험예> Experimental Example

[세포배양]  [Cell Culture]

사람의 자궁경부암 상피 세포인 HeLa 세포주, 사람의 폐암 세포인 A549 세포주, 사람의 피부 흑색종 세포인 WM 266.4 세포주, 케라틴 분비형 자궁경부암 세포인 KB세포주, 사람의 혈액성 백혈병 세포인 K562 세포주, 사람의 골수성 백혈병 세포인 TF-1세포주는 ATCC (American Type Culture Collection, USA)로부터 구입하여 사용하였으며, 쥐의 간암 세포인 Hepa 1-6 세포주는 DSMZ (German Collection of Microorganisms and Cell Cultures, Germany)로부터 구입하여 사용하였다. HeLa, A549, K562, TF-1 세포주는 RPMI(Gibco, USA), Hepa 1-6 세포주는 DMEM(Dulbecco's modified eagles medium, Gibco, USA), WM266.4, KB 세포주는 MEM(Minimum Essential Medium, Gibco, USA)에 10% 우태아 혈청 w/v (HyClone laboratories Inc, USA)과 100 unit/ml 페니실린 또는 100㎍/ml 스트렙토마이신을 포함하여 배양하였다. HeLa cell line, human cervical cancer epithelial cell, A549 cell line, human lung cancer cell, WM 266.4 cell line, human skin melanoma cell, KB cell line, keratin-secreting cervical cancer cell, K562 cell line, human blood leukemia cell, human TF-1 cell line, a myeloid leukemia cell, was purchased from ATCC (American Type Culture Collection, USA). Hepa 1-6 cell line, a mouse liver cancer cell, was purchased from German Collection of Microorganisms and Cell Cultures, Germany (DSMZ). Was used. HeLa, A549, K562, TF-1 cell line RPMI (Gibco, USA), Hepa 1-6 cell line DMEM (Dulbecco's modified eagles medium, Gibco, USA), WM266.4, KB cell line MEM (Minimum Essential Medium, Gibco , USA) were cultured with 10% fetal calf serum w / v (HyClone laboratories Inc, USA) and 100 unit / ml penicillin or 100 μg / ml streptomycin.

[실험예 1] 작은 간섭 리보핵산과 핵산 전달체의 복합체 형성여부 측정 Experimental Example 1 Measurement of Complex Formation of Small Interfering Ribonucleic Acid and Nucleic Acid Carrier

200 나노그램의 작은 간섭 리보핵산과 본 발명의 핵산 전달체의 복합체를 형성하기 위해 작은 간섭 리보핵산과 본 발명의 핵산 전달체 (실시예 2, 12, 26)의 무게비를 달리하여 (1:1~1:60) 혼합한 후 실온에서 20분간 방치한 후 아가로즈 젤에 전기영동 하여 확인하였다. 핵산은 EtBr로 염색하여 아가로스 젤 상에서의 위치를 확인 하였다. In order to form a complex of 200 nanograms of small interfering ribonucleic acid and the nucleic acid carrier of the present invention, by varying the weight ratio of the small interfering ribonucleic acid and the nucleic acid carrier of the present invention (Examples 2, 12, 26) (1: 1 to 1) : 60) After mixing, the mixture was allowed to stand at room temperature for 20 minutes, followed by electrophoresis on an agarose gel. Nucleic acid was stained with EtBr to confirm the position on the agarose gel.

본 실험 수행결과, 도 3[실시예 2-(A), 실시예 12-(B), 실시예 26-(C)]에서 보는 바와 같이 본 발명의 핵산 전달체의 양이 증가할수록 작은 간섭 리보핵산과 핵산 전달체의 복합체의 양이 증가하여 결합체를 형성하지 않는 작은 간섭 리보핵산의 양이 감소하는 결과를 확인 할 수 있었다. As a result of this experiment, as shown in FIG. 3 (Example 2- (A), Example 12- (B), and Example 26- (C)], as the amount of the nucleic acid carrier of the present invention was increased, small interfering ribonucleic acid was increased. Increasing the amount of the complex and the nucleic acid transporter was confirmed to reduce the amount of small interfering ribonucleic acid does not form a conjugate.

[실험예 2] 작은 간섭 리보핵산과 본 발명의 핵산 전달체의 복합체의 입자크기 측정 Experimental Example 2 Measurement of Particle Size of Complex of Small Interfering Ribonucleic Acid and Nucleic Acid Carrier of the Invention

200 나노그램의 작은 간섭 리보핵산과 본 발명의 핵산 전달체 (실시예 16, 23)의 무게비를 1:40으로 하여 실온에서 20분간 복합체를 형성한 후 3 밀리리터의 인산 완충용액을 첨가한 후 동적광산란 장비 (ELS-8000)를 이용하여 복합체의 입자 경을 측정하였다. After forming a complex at room temperature with a ratio of 200 nanograms of small interfering ribonucleic acid and a nucleic acid carrier of the present invention (Examples 16 and 23) at room temperature for 20 minutes, 3 milliliters of a phosphate buffer solution was added, followed by dynamic light scattering. The particle size of the composite was measured using the instrument (ELS-8000).

본 실험 수행결과, 도 4[실시예 16-(A), 실시예 23-(B)]에서 보는 바와 같이 작은 간섭 리보핵산과 본 발명의 핵산 전달체의 복합체 실시예 16의 경우 입자경은 223 나노미터의 크기를 갖는 것으로 확인되었으며, 실시예 23의 경우에는 핵산 전달체의 복합체 크기가 243 나노미터의 크기를 갖는 결과를 확인 할 수 있었다. As a result of this experiment, as shown in FIG. 4 (Example 16- (A), Example 23- (B)], the particle size of the complex Example 16 of the small interfering ribonucleic acid and the nucleic acid carrier of the present invention was 223 nanometers. It was confirmed that it has a size of, in the case of Example 23 was confirmed that the result of the complex size of the nucleic acid carrier having a size of 243 nanometers.

[실험예 3] 형광마커로 표지된 작은 간섭 리보핵산을 이용한 핵산 전달 효율 평가 Experimental Example 3 Evaluation of Nucleic Acid Delivery Efficiency Using Small Interfering Ribonucleic Acid Labeled with Fluorescent Markers

3-1. HeLa 세포주에서의 작은 간섭 리보핵산의 전달 효율 평가 3-1. Evaluation of Delivery Efficiency of Small Interfering Ribonucleic Acids in HeLa Cell Lines

HeLa 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1 (LipofectamineTM2000, Invitrogen, USA)과 실시예 7, 21에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포의 배약액을 제거한 후 200㎕씩 새로운 배양액으로 교체하여 준 후 형광 현미경으로 리보핵산 전달 효율을 관찰하였다. HeLa cell lines were seeded 2.5 x 10 mm / well into a 48 well plate the day before the experiment, and when the cells of each plate were grown uniformly by 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube. 5 pmoles of Block-iT (Invitrogen, USA), a small interfering ribonucleic acid substance labeled with a fluorescent marker, and the nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Examples 7, 21 were weight ratio 1:60. Each was added to this. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. After removing the culture solution of the cultured cells were replaced with a new culture medium 200μl each and observed the efficiency of ribonucleic acid delivery by fluorescence microscope.

도 5는 비교예 1[(A) 및 (B)]과 실시예 7[(C) 및 (D)], 21[(E) 및 (F)]로부 터 제조된 핵산 전달체의 핵산 전달 효율을 형광 현미경(DMIL, Leica, Germany)과 위상차 현미경으로 관찰한 것으로 도 5의 A, C, E 사진은 위상차 현미경 사진이고, 도 5의 B, D, F는 형광 마커로 표지된 작은 간섭 리보핵산의 세포내 전달을 보여주는 형광 현미경 사진이다. 본 실험 수행 결과, 도 5에서 보는 바와 같이 실시예 7, 21로부터 제조된 핵산 전달체의 HeLa 세포주에 대한 핵산 전달 효율이 비교예 1 보다 향상된 작은 간섭 리보핵산의 전달효율을 갖는 다는 사실을 알 수 있다. Figure 5 shows the nucleic acid delivery efficiency of nucleic acid carriers prepared from Comparative Example 1 [(A) and (B)] and Examples 7 [(C) and (D)], 21 [(E) and (F)]. Observed by a fluorescence microscope (DMIL, Leica, Germany) and a phase contrast microscope, A, C, and E images of Figure 5 are phase contrast micrographs, B, D, F of Figure 5 is a small interfering ribonucleic acid labeled with a fluorescent marker Fluorescence micrograph showing intracellular delivery. As a result of this experiment, it can be seen that the nucleic acid delivery efficiency of the nucleic acid carriers prepared in Examples 7 and 21 to the HeLa cell line as shown in FIG. 5 has a smaller efficiency of delivery of interfering ribonucleic acid than Comparative Example 1. .

3-2. Hepa 1-6 세포주에서의 작은 간섭 리보핵산의 전달 효율 평가 3-2. Evaluation of Delivery Efficiency of Small Interfering Ribonucleic Acids in Hepa 1-6 Cell Line

Hepa 1-6 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1 (LipofectamineTM2000, Invitrogen, USA)과 실시예 25, 33에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포의 배약액을 제거한 후 200㎕씩 새로운 배양액으로 교체하여 준 후 형광 현미경으로 리보핵산 전달 효율을 관찰하였다. Hepa 1-6 cell lines were seeded at 2.5 × 10 cells per well into 48 well plates the day before the experiment, and the cells of each plate grown uniformly by 60-70%. 5 μl each of the small interfering ribonucleic acid substance Block-iT (Invitrogen, USA) labeled with a fluorescent marker and the nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Examples 25 and 33 Each was added to be 1:60. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. After removing the culture solution of the cultured cells were replaced with a new culture medium 200μl each and observed the efficiency of ribonucleic acid delivery by fluorescence microscope.

도 6은 비교예 1[(A) 및 (B)]과 실시예 25[(C) 및 (D)], 실시예 33[(E) 및 (F)]으로부터 제조된 핵산 전달체의 핵산 전달 효율을 형광 현미경(DMIL, Leica, Germany)과 위상차 현미경으로 관찰한 것으로 도 6의 A, C, E사진은 위상차 현미경 사진이고, 도 6의 B, D, F 사진은 형광 마커로 표지된 작은 간섭 리보핵산의 세포내 전달을 보여주는 형광 현미경 사진이다. 본 실험 수행 결과, 도 6C와 6D에서 보는 바와 같이 실시예 25로부터 제조된 핵산 전달체의 Hepa 1-6 세포주에 대한 핵산 전달효율이 비교예 1 (도 6A, 6B) 보다 향상된 핵산 전달효율을 갖는 다는 사실을 알 수 있었다. 또한, 실시예 33으로부터 제조된 핵산 전달체의 경우 도 6E와 도 6F에서 나타난 바와 같이 Hepa 1-6 세포주에 대한 핵산 전달 효율이 비교예 1 (도 6A, 6B)보다 향상된 작은 간섭 리보핵산의 전달효율을 갖는 다는 사실을 알 수 있다. 6 shows nucleic acid delivery efficiency of nucleic acid carriers prepared from Comparative Example 1 [(A) and (B)] and Example 25 [(C) and (D)], Example 33 [(E) and (F)]. Was observed with a fluorescence microscope (DMIL, Leica, Germany) and a phase contrast microscope. A, C, and E images of FIG. 6 are phase contrast micrographs, and B, D, and F images of FIG. 6 are small interference ribs labeled with fluorescent markers. Fluorescence micrograph showing intracellular delivery of nucleic acid. As a result of this experiment, as shown in FIGS. 6C and 6D, the nucleic acid delivery efficiency of the nucleic acid carrier prepared in Example 25 to the Hepa 1-6 cell line has improved nucleic acid delivery efficiency than that of Comparative Example 1 (FIGS. 6A and 6B). I could tell the truth. In addition, in the case of the nucleic acid carrier prepared from Example 33, as shown in FIGS. 6E and 6F, the nucleic acid delivery efficiency of Hepa 1-6 cell line was improved compared to that of Comparative Example 1 (FIGS. 6A and 6B). It can be seen that

3-3. WM266.4 세포주에서의 작은 간섭 리보핵산의 전달 효율 평가 3-3. Evaluation of Delivery Efficiency of Small Interfering Ribonucleic Acids in WM266.4 Cell Line

WM266.4 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1 (LipofectamineTM2000, Invitrogen, USA)과 실시예 5, 19에서 제조된 핵산 전달체 용액을 무게비가 1:50이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포의 배약액을 제거한 후 200㎕씩 새로운 배양액으로 교체하여 준 후 형광 현미경으로 리보핵산 전달 효율을 관찰하였다. When the WM266.4 cell line was seeded at 2.5 x 10 mm / well into 48 well plates on the day before the experiment, and the cells of each plate were uniformly grown by 60-70%, 50 µl of serum-free medium was added to the Eppendorf tube. The nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Examples 5 and 19, each containing 5 pmole of small interfering ribonucleic acid substance labeled with fluorescent markers and labeled with fluorescent markers, had a weight ratio of 1 Each was added so as to be 50. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. After removing the culture solution of the cultured cells were replaced with a new culture medium 200μl each and observed the efficiency of ribonucleic acid delivery by fluorescence microscope.

도 7은 비교예 1[(A) 및 (B)]과 실시예 5[(C) 및 (D)]와 실시예 19 [(E) 및 (F)]로부터 제조된 핵산 전달체의 핵산 전달 효율을 형광 현미경(DMIL, Leica, Germany)과 위상차 현미경으로 관찰한 것으로 형광 마커로 표지된 작은 간섭 리보핵산의 세포내 전달을 보여주는 위상차 현미경 및 형광 현미경 사진이다. 본 실험 수행 결과, 도 7C와 7D에서 보는 바와 같이 실시예 5로부터 제조된 핵산 전달체의 WM266.4 세포주에 대한 핵산 전달 효율이 비교예 1 (도 7A, 7B)보다 향상된 작은 간섭 리보핵산의 전달효율을 갖는다는 사실을 알 수 있다. 또한, 도 7E와 7F에서 보는 바와 같이 실시예 19로부터 제조된 핵산 전달체의 전달효율을 확인한 결과 비교예 1 (도 7A, 7B)보다 향상된 작은 간섭 리보핵산의 전달효율을 갖는다는 사실을 알 수 있다. 7 shows nucleic acid delivery efficiency of nucleic acid carriers prepared from Comparative Example 1 [(A) and (B)] and Example 5 [(C) and (D)] and Example 19 [(E) and (F)]. Observed by fluorescence microscopy (DMIL, Leica, Germany) and phase contrast microscopy, which is a phase contrast microscopy and fluorescence micrograph showing intracellular delivery of small interfering ribonucleic acid labeled with a fluorescent marker. As a result of the present experiment, as shown in FIGS. 7C and 7D, the nucleic acid delivery efficiency of the nucleic acid delivery agent prepared in Example 5 was improved for the WM266.4 cell line, and the transfer efficiency of the interference ribonucleic acid was smaller than that of Comparative Example 1 (FIGS. 7A and 7B). It can be seen that In addition, as shown in FIGS. 7E and 7F, as a result of confirming the transfer efficiency of the nucleic acid carrier prepared from Example 19, it can be seen that the transfer efficiency of the interfering ribonucleic acid is improved compared to that of Comparative Example 1 (FIGS. 7A and 7B). .

[실험예 4] 형광 유세포 분석법 (Fluorescence Activated Cell Sorting, FACS)을 이용한 작은 간섭 리보핵산의 전달 효율 측정 Experimental Example 4 Measurement of Delivery Efficiency of Small Interfering Ribonucleic Acid Using Fluorescence Activated Cell Sorting (FACS)

4-1. A549 세포주에서의 형광 유세포 분석법 (Fluorescence Activated Cell Sorting, FACS)을 이용한 작은 간섭 리보핵산의 전달 효율 측정 4-1. Measurement of Delivery Efficiency of Small Interfering Ribonucleic Acid Using Fluorescence Activated Cell Sorting (FACS) in A549 Cell Line

A549 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1(LipofectamineTM2000, Invitrogen, USA)과 실시예 29에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포의 배약액을 제거한 후 200㎕씩 인산 완충용액으로 교체하여 준 후 배양된 세포를 수집하였으며, 세포를 수집한 후 인산 완충용액으로 2번 세척하였다. 형광 표지된 작은 간섭 리보핵산이 들어간 세포들을 형광 유세포 분석기인 BD FACS CALIBUR (BD Bioscience, USA)를 사용하여 형광 강도 피크의 이동에 의한 세포내 전달 효율을 분석하였다. 이를 도 8에 나타내었다. When the A549 cell line was seeded by 2.5 × 10 cells per well into 48 well plates on the day before the experiment, and the cells of each plate were uniformly grown by 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube. 5 pmoles of Block-iT (Invitrogen, USA), a small interfering ribonucleic acid substance labeled with a fluorescent marker, and the nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Example 29 were weight ratio 1:60. Each added. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. After removal of the culture solution of the cultured cells were replaced with phosphate buffer solution 200μL each cultured cells were collected, and the cells were collected and washed twice with phosphate buffer solution. Cells containing fluorescently labeled small interfering ribonucleic acids were analyzed for intracellular delivery efficiency by shift of fluorescence intensity peak using a fluorescence flow cytometer, BD FACS CALIBUR (BD Bioscience, USA). This is shown in FIG. 8.

도 8의 도면에서 세포에 아무 처리하지 않은 미처리군 (도 8A)은 대조군으로 리보핵산이 세포 내로 전달되지 않아 피크가 거의 이동하지 않았고 (1.12% 이동함), 도 8B의 비교예 1을 사용한 실험군에서는 형광이 표지된 작은 간섭 리보핵산의 전달 효율이 77.59%인 것으로 확인 되었다. 한편, 본 발명의 실시예 29 (도 8C)의 처리군의 경우 각각 91.74%를 나타내어 비교예 1 처리군에 비하여 향상된 세포내 전달효율을 갖는 것으로 확인되었다. In the figure of FIG. 8, the untreated group (FIG. 8A), which was not treated to the cells, did not transfer ribonucleic acid into the cells as a control, and almost no peak shifted (1.12% shifted), and the experimental group using Comparative Example 1 of FIG. 8B. In fluorescence-labeled small interfering ribonucleic acid, the transmission efficiency was 77.59%. On the other hand, the treated group of Example 29 (FIG. 8C) of the present invention was 91.74%, which was confirmed to have improved intracellular delivery efficiency compared to the comparative example 1 treated group.

따라서 본 발명의 실시예 29에서 제조된 핵산 전달체가 비교예 1 보다 우수한 리보핵산 전달 효율을 가짐을 알 수 있었다. Therefore, it was found that the nucleic acid carrier prepared in Example 29 of the present invention had superior ribonucleic acid delivery efficiency than Comparative Example 1.

4-2. KB 세포주에서의 형광 유세포 분석법 (Fluorescence Activated Cell Sorting, FACS)을 이용한 작은 간섭 리보핵산의 전달 효율 측정 4-2. Measurement of Delivery Efficiency of Small Interfering Ribonucleic Acid Using Fluorescence Activated Cell Sorting (FACS) in KB Cell Lines

KB 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1 (LipofectamineTM2000, Invitrogen, USA)과 실시예 39에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포의 배약액을 제거한 후 200㎕씩 인산 완충용액으로 교체하여 준 후 배양된 세포를 수집하였으며, 세포를 수집한 후 인산 완충용액으로 2번 세척하였다. 형광 표지된 작은 간섭 리보핵산이 들어간 세포들을 형광 유세포 분석기인 BD FACS CALIBUR (BD Bioscience, USA)를 사용하여 형광 강도 피크의 이동에 의한 세포내 전달 효율을 분석하였다. 이를 도 9에 나타내었다. KB cells were seeded 2.5 × 10 mm / well into 48 well plates on the day before the experiment, and when the cells of each plate grew uniformly by 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube. 5 pmoles of Block-iT (Invitrogen, USA), a small interfering ribonucleic acid substance labeled with a fluorescent marker, and the nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Example 39 were weight ratio 1:60. Each added. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. After removal of the culture solution of the cultured cells were replaced with phosphate buffer solution 200μL each cultured cells were collected, and the cells were collected and washed twice with phosphate buffer solution. Cells containing fluorescently labeled small interfering ribonucleic acids were analyzed for intracellular delivery efficiency by shift of fluorescence intensity peak using a fluorescence flow cytometer, BD FACS CALIBUR (BD Bioscience, USA). This is shown in FIG. 9.

도 9의 도면에서 세포에 아무 처리하지 않은 미처리군 (도 9A)은 대조군으로 리보핵산이 세포 내로 전달되지 않아 피크가 거의 이동하지 않았고 (0.22% 이동함), 도 9B의 비교예 1을 사용한 그래프에서는 형광이 표지된 작은 간섭 리보핵산의 전달 효율이 80.79%인 것으로 확인 되었다. 한편, 본 발명의 실시예 39의 처리군의 경우 95.38%를 나타내어 비교예 1 (도 9B)의 처리군에 비하여 보다 향상된 세포내 전달효율을 갖는 것으로 확인되었다. In the figure of FIG. 9, the untreated group (FIG. 9A), which was not treated to cells, did not transfer ribonucleic acid into the cells as a control, and almost no peak shifted (0.22% shifted), and the graph using Comparative Example 1 of FIG. In fluorescence-labeled small interfering ribonucleic acid, the transmission efficiency was found to be 80.79%. On the other hand, the treatment group of Example 39 of the present invention showed 95.38%, it was confirmed to have an improved intracellular delivery efficiency compared to the treatment group of Comparative Example 1 (Fig. 9B).

따라서 본 발명의 실시예 39(도 9C)에서 제조된 핵산 전달체가 비교예 1 보 다 우수한 리보핵산 전달 효율을 가짐을 알 수 있었다. Therefore, it was found that the nucleic acid carrier prepared in Example 39 (FIG. 9C) of the present invention had superior ribonucleic acid delivery efficiency than Comparative Example 1.

4-3. K562 세포주에서의 형광 유세포 분석법 (Fluorescence Activated Cell Sorting, FACS)을 이용한 작은 간섭 리보핵산의 전달 효율 측정 4-3. Measurement of Delivery Efficiency of Small Interfering Ribonucleic Acid Using Fluorescence Activated Cell Sorting (FACS) in K562 Cell Lines

K562 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1(LipofectamineTM2000, Invitrogen, USA)과 실시예 13에서 제조된 핵산 전달체 용액을 무게비가 1:80이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포를 수집한 후 인산 완충용액으로 2번 세척하였다. 형광 표지된 작은 간섭 리보핵산이 들어간 세포들을 형광 유세포 분석기인 BD FACS CALIBUR (BD Bioscience, USA)를 사용하여 형광 강도 피크의 이동에 의한 세포내 전달 효율을 분석하였다. 이를 도 10에 나타내었다. When K562 cell lines were seeded at 2.5 × 10 mm / well into 48 well plates the day before the experiment, and the cells of each plate were grown uniformly by 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube. 5 pmoles of Block-iT (Invitrogen, USA), a small interfering ribonucleic acid substance labeled with a fluorescent marker, and the nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Example 13 were weight ratio 1:80. Each added. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. The cultured cells were collected and washed twice with phosphate buffer. Cells containing fluorescently labeled small interfering ribonucleic acids were analyzed for intracellular delivery efficiency by shift of fluorescence intensity peak using a fluorescence flow cytometer, BD FACS CALIBUR (BD Bioscience, USA). This is shown in FIG. 10.

도 10의 도면에서 세포에 아무 처리하지 않은 미처리군 (도 10A)은 대조군으로 리보핵산이 세포 내로 전달되지 않아 피크가 거의 이동하지 않았고 (0.38%), 도 10B의 비교예 1을 사용한 처리군의 경우 형광이 표지된 작은 간섭 리보핵산의 전달 효율이 48.21%인 것으로 확인 되었다. In the figure of FIG. 10, the untreated group (FIG. 10A), which was not treated to cells, had no transfer of ribonucleic acid into the cells as a control, and almost no peak shifted (0.38%). In this case, the delivery efficiency of fluorescently labeled small interfering ribonucleic acid was found to be 48.21%.

한편, 도 10C의 결과에서 나타나듯이 본 발명의 실시예 13 (도 10C)의 처리군의 경우 83.67%를 나타내어 비교예 1의 처리군에 비하여 향상된 세포내 전달효율을 갖는 것으로 확인되었다. Meanwhile, as shown in the results of FIG. 10C, the treatment group of Example 13 (FIG. 10C) of the present invention exhibited 83.67% and was found to have improved intracellular delivery efficiency compared to the treatment group of Comparative Example 1.

따라서 본 발명의 실시예 13에서 제조된 핵산 전달체가 비교예 1보다 우수한 리보핵산 전달 효율을 가짐을 알 수 있었다. Therefore, it was found that the nucleic acid carrier prepared in Example 13 of the present invention had superior ribonucleic acid delivery efficiency than Comparative Example 1.

4-4. TF-1 세포주에서의 형광 유세포 분석법 (Fluorescence Activated Cell Sorting, FACS)을 이용한 작은 간섭 리보핵산의 전달 효율 측정 4-4. Measurement of Delivery Efficiency of Small Interfering Ribonucleic Acid Using Fluorescence Activated Cell Sorting (FACS) in TF-1 Cell Lines

TF-1 세포주를 실험 전날 48 웰 플레이트에 웰 당 2.5×10⁴개씩 분주(seeding)하고 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50 ㎕씩을 넣고 형광 마커로 표지된 작은 간섭 리보핵산 물질인 Block-iT (Invitrogen, USA) 5pmole씩과 비교예 1 (LipofectamineTM2000, Invitrogen, USA)과 실시예 15에서 제조된 핵산 전달체 용액을 무게비가 1:80이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하였다. 이렇게 제조된 복합체를 웰 플레이트에 가하여 37℃의 CO₂배양기에서 24시간 동안 배양하였다. 배양된 세포를 수집한 후 인산 완충용액으로 2번 세척하였다. 형광 표지된 작은 간섭 리보핵산이 들어간 세포들을 형광 유세포 분석기인 BD FACS CALIBUR (BD Bioscience, USA)를 사용하여 형광 강도 피크의 이동에 의한 세포내 전달 효율을 분석하였다. 이를 도 11에 나타내었다. 50 μl of serum-free medium in the Eppendorf tube when TF-1 cell lines were seeded at 2.5 × 10 cells per well into 48 well plates the day before the experiment and the cells of each plate grew uniformly by 60-70%. The nucleic acid carrier solution prepared in Comparative Example 1 (LipofectamineTM2000, Invitrogen, USA) and Example 15 with Block-iT (Invitrogen, USA), a small interfering ribonucleic acid substance labeled with a fluorescent marker, was weighed in a ratio of 1:80. Each was added so as to. These were slowly pipetted and mixed and left at room temperature for 20 minutes. The complex thus prepared was added to a well plate and incubated in a CO 2 incubator at 37 ° C. for 24 hours. The cultured cells were collected and washed twice with phosphate buffer. Cells containing fluorescently labeled small interfering ribonucleic acids were analyzed for intracellular delivery efficiency by shift of fluorescence intensity peak using a fluorescence flow cytometer, BD FACS CALIBUR (BD Bioscience, USA). This is shown in FIG. 11.

도 11의 도면에서 세포에 아무 처리하지 않은 미처리군 (도 11A)은 대조군으로 리보핵산이 세포 내로 전달되지 않아 피크가 거의 이동하지 않았고 (1.03% 이동함), 도 11B의 비교예 1을 사용한 그래프에서는 형광이 표지된 작은 간섭 리보핵산의 전달 효율이 57.73%인 것으로 확인 되었다. 한편, 본 발명의 실시예 15의 처리군의 경우 도 11C에서 확인할 수 있듯이 87.82%를 나타내어 비교예 1의 처리군에 비하여 향상된 세포내 전달효율을 갖는 것으로 확인되었다. In the figure of FIG. 11, the untreated group (FIG. 11A), which was not treated to the cells, did not transfer ribonucleic acid into the cells as a control, and almost no peak shifted (1.03% shifted), and the graph using Comparative Example 1 of FIG. 11B was used. In fluorescence-labeled small interfering ribonucleic acid, the transmission efficiency was found to be 57.73%. On the other hand, the treatment group of Example 15 of the present invention showed 87.82% as shown in Figure 11C it was confirmed to have an improved intracellular delivery efficiency compared to the treatment group of Comparative Example 1.

따라서 본 발명의 실시예 15에서 제조된 핵산 전달체가 비교예 1 보다 우수한 리보핵산 전달 효율을 가짐을 알 수 있었다. Therefore, it was found that the nucleic acid carrier prepared in Example 15 of the present invention had superior ribonucleic acid delivery efficiency than Comparative Example 1.

[실험예 5] 역전사 중합효소 연쇄반응을 이용한 작은간섭 리보핵산 전달 효능 평가Experimental Example 5 Evaluation of Small Interfering Ribonucleic Acid Delivery Efficacy Using Reverse Transcriptase Polymerase Chain Reaction

5-1. HeLa 세포에서 역전사 중합효소 연쇄반응을 이용한 작은간섭 리보핵산 전달 효능 평가 5-1. Evaluation of Small Interfering Ribonucleic Acid Delivery Efficacy Using Reverse Transcriptase Polymerase Chain Reaction in HeLa Cells

HeLa 세포주를 실험 전날 24 웰 플레이트에 웰 당 세포를 5×10⁴씩 분주(seeding)하였다. 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50㎕씩을 넣고, 서바이빈을 타겟하는 siRNA 20 pmole을 비교예 1 (LipofectamineTM2000과 siRNA 복합체 처리군)과 실시예 9과 실시예 22에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. 서바이빈 (survivin) 유전자(Gene bank accession number: NM_001168)의 발현 억제를 유도하기 위한 siRNA는 삼천리제약 (Samchully Pharmaceuticals, Seoul, Korea)에서 구입하여 사용하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하고 이렇게 제조된 복합체를 웰 플레이트에 첨가하여 37 ℃의 CO₂세포배양기에서 24시간 동안 배양하였다. 24시간 후 Trizol 시약(Invitrogen, Carlsbad, CA, USA)을 사용하여 세포내에 존재하는 전체 메신저 리보핵산 (mRNA)을 분리하였으며, 이 mRNA는 AccuPowerRT PreMix (Bioneer, Daejeon, Korea)를 사용하여 cDNA로 역전사 하였다. 서바이빈(survivin)에 특이적인 프라이머의 서열은 5'-GGACCACCGCATCTCTACAT-3'(정방향), 5'-CTTTCTCCGCAGTTTCCTCA-3'(역방향)이며 중합효소연쇄반응은 95℃에서 5분 반응 후, 95℃에서 1분, 59℃에서 1분, 72℃에서 30초를 30번 반복한 후 72℃에서 5분 더 반응시켜주었다. 생성물의 크기는 347 염기쌍이었다. 서바이빈(survivin) 유전자 발현의 정도는 서바이빈 특이적인 연쇄반응 생성물의 밴드 밀도를 GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 유전자를 증폭하여 나타나는 밴드를 비교군으로 사용하여 정량적인 발현의 변화량을 측정하였다. HeLa cell lines were seeded 5 × 10 μs of cells per well in 24 well plates the day before the experiment. When the cells of each plate grew uniformly by about 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube, and 20 pmoles of siRNA targeting survivin were compared to Comparative Example 1 (LipofectamineTM2000 and siRNA complex treatment). Group) and the nucleic acid carrier solution prepared in Example 9 and Example 22 were added so that the weight ratio is 1:60. SiRNA for inducing expression of survivin gene (Gene bank accession number: NM_001168) was purchased from Samchully Pharmaceuticals, Seoul, Korea. After slowly pipetting and mixing, the mixture was allowed to stand at room temperature for 20 minutes, and the complex thus prepared was added to a well plate and incubated in a CO 2 cell incubator at 37 ° C. for 24 hours. After 24 hours, total messenger ribonucleic acid (mRNA) present in cells was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and this mRNA was reverse transcribed into cDNA using AccuPowerRT PreMix (Bioneer, Daejeon, Korea). It was. The primers specific for survivin are 5'-GGACCACCGCATCTCTACAT-3 '(forward) and 5'-CTTTCTCCGCAGTTTCCTCA-3' (reverse), and the polymerase chain reaction was performed at 95 ° C for 5 minutes, and then 95 ° C. 1 minute, 59 minutes at 1 ℃, 30 seconds at 72 ℃ was repeated 30 times and further reacted at 72 ℃ 5 minutes. The size of the product was 347 base pairs. The expression level of survivin gene was determined by comparing the band density of survivin-specific chain reaction product with the band amplified by GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene as a comparison group. Measured.

도 12는 미처리군과 비교예 1과 실시예 9와 22를 사용한 복합체를 처리한 경우 HeLa 세포내에서 타겟 유전자인 서바이빈의 전사체 발현을 비교한 것이다. 대조군은 미처리군과 비교예 1을 사용하였다. Figure 12 compares the expression of transcripts of survivin, a target gene, in HeLa cells when treated with the complex using the untreated group and Comparative Example 1 and Examples 9 and 22. As a control group, Comparative Example 1 and the untreated group were used.

미처리 대조군에 비해 실시예 9와 22를 사용한 복합체 처리군의 경우 서바이빈 유전자의 발현양이 각각 16.3%와 12.8%와 같이 현저히 낮은 것으로 확인되어 비교예 1에서 나타난 37.6% 발현양에 비해 서바이빈을 타겟하는 작은간섭 리보핵산의 전달효율이 우수한 것으로 확인되었다. In the complex treated group using Examples 9 and 22 compared to the untreated control group, the expression levels of survivin genes were remarkably low, such as 16.3% and 12.8%, respectively. It was confirmed that the delivery efficiency of small interfering ribonucleic acid targeting the bean was excellent.

이와 같은 결과에서 알 수 있듯이, 실시예 9와 22에서 제조된 핵산 전달체가 HeLa 세포 내로 작은간섭 리보핵산물질을 비교예 1 보다 우수한 효율로 전달하여 표적유전자의 발현을 선택적으로 억제시킴을 알 수 있었다. As can be seen from these results, it was found that the nucleic acid carriers prepared in Examples 9 and 22 deliver small interfering ribonucleic acid into HeLa cells with better efficiency than Comparative Example 1 to selectively inhibit the expression of target genes. .

5-2. WM 266.4 세포에서 역전사 중합효소 연쇄반응을 이용한 작은간섭 리보핵산 전달 효능 평가 5-2. Evaluation of Small-Interfering Ribonucleic Acid Delivery Efficacy by Reverse Transcription Polymerase Chain Reaction in WM 266.4 Cells

WM 266.4 세포주를 실험 전날 24 웰 플레이트에 웰 당 세포를 5×10⁴씩 분주(seeding)하였다. 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50㎕씩을 넣고, 서바이빈을 타겟하는 siRNA 20 pmole을 비교예 1 (LipofectamineTM2000과 siRNA 복합체 처리군)과 실시예 18과 실시예 36에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. WM 266.4 cell lines were seeded 5 × 10 μs of cells per well in 24 well plates the day before the experiment. When the cells of each plate grew uniformly by about 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube, and 20 pmoles of siRNA targeting survivin were compared to Comparative Example 1 (LipofectamineTM2000 and siRNA complex treatment). Group) and the nucleic acid carrier solutions prepared in Examples 18 and 36 were added so that the weight ratio is 1:60.

서바이빈 (survivin) 유전자(Gene bank accession number: NM_001168)의 발현 억제를 유도하기 위한 siRNA는 삼천리제약 (Samchully Pharmaceuticals, Seoul, Korea)에서 구입하여 사용하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하고 이렇게 제조된 복합체를 웰 플레이트에 첨가하여 37 ℃의 CO₂세포배양기에서 24시간 동안 배양하였다. 24시간 후 Trizol 시약(Invitrogen, Carlsbad, CA, USA)을 사용하여 세포내에 존재하는 전체 메신저 리보핵산 (mRNA)을 분리하였으며, 이 mRNA는 AccuPowerRT PreMix (Bioneer, Daejeon, Korea)를 사용하여 cDNA로 역전사 하였다. SiRNA for inducing expression of survivin gene (Gene bank accession number: NM_001168) was purchased from Samchully Pharmaceuticals, Seoul, Korea. After slowly pipetting and mixing, the mixture was allowed to stand at room temperature for 20 minutes, and the complex thus prepared was added to a well plate and incubated in a CO 2 cell incubator at 37 ° C. for 24 hours. After 24 hours, total messenger ribonucleic acid (mRNA) present in cells was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and this mRNA was reverse transcribed into cDNA using AccuPowerRT PreMix (Bioneer, Daejeon, Korea). It was.

도 13은 미처리군과 비교예 1과 실시예 18과 36을 사용한 복합체를 처리한 경우 WM 266.4 세포내에서 타겟 유전자인 서바이빈의 전사체 발현을 비교한 것이다. 대조군은 미처리군과 비교예 1을 사용하였다. FIG. 13 compares the expression of transcripts of survivin, a target gene, in WM 266.4 cells when the untreated group and the complexes using Comparative Examples 1 and 18 and 36 were treated. FIG. As a control group, Comparative Example 1 and the untreated group were used.

미처리 대조군에 비해 실시예 18과 36을 사용한 복합체 처리군의 경우 서바이빈 유전자의 발현양이 각각 4.6%와 5.7% 같이 현저히 낮은 것으로 확인되어 비교예 1에서 나타난 20.3% 발현양에 비해 서바이빈을 타겟하는 작은간섭 리보핵산의 전달효율이 우수한 것으로 확인되었다. In the complex treated group using Examples 18 and 36, the expression level of survivin gene was significantly lower, such as 4.6% and 5.7%, respectively, compared to the untreated control group. It was confirmed that the delivery efficiency of small interfering ribonucleic acid that targets.

이와 같은 결과에서 알 수 있듯이, 실시예 18과 36에서 제조된 핵산 전달체가 WM 266.4 세포 내로 작은간섭 리보핵산물질을 비교예 1 보다 우수한 효율로 전달하여 표적유전자의 발현을 선택적으로 억제시킴을 알 수 있었다. As can be seen from these results, it can be seen that the nucleic acid carriers prepared in Examples 18 and 36 deliver small interfering ribonucleic acid into WM 266.4 cells with better efficiency than Comparative Example 1 to selectively inhibit the expression of the target gene. there was.

5-3. KB 세포에서 역전사 중합효소 연쇄반응을 이용한 작은간섭 리보핵산 전달 효능 평가 5-3. Evaluation of Small Interfering Ribonucleic Acid Transfer Efficacy Using Reverse Transcriptase Polymerase Chain Reaction in KB Cells

KB 세포주를 실험 전날 24 웰 플레이트에 웰 당 세포를 5×10⁴씩 분주(seeding)하였다. 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜도르프 튜브에 혈청이 포함되지 않은 배지 50㎕씩을 넣고, 서바이빈을 타겟하는 siRNA 20 pmole을 비교예 1 (LipofectamineTM2000과 siRNA 복합체 처리군)과 실시예 24와 실시예 38에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. KB cell lines were seeded 5 × 10 μs of cells per well in 24 well plates the day before the experiment. When the cells of each plate grew uniformly by about 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube, and 20 pmoles of siRNA targeting survivin were compared to Comparative Example 1 (LipofectamineTM2000 and siRNA complex treatment). Group) and the nucleic acid carrier solutions prepared in Examples 24 and 38 were added so that the weight ratio was 1:60.

이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하고 이렇게 제조된 복합체를 웰 플레이트에 첨가하여 37 ℃의 CO₂세포배양기에서 24시간 동안 배양하였다. 24시간 후 Trizol 시약(Invitrogen, Carlsbad, CA, USA)을 사용하여 세포내에 존재하는 전체 메신저 리보핵산 (mRNA)을 분리하였으며, 이 mRNA는 AccuPowerRT PreMix (Bioneer, Daejeon, Korea)를 사용하여 cDNA로 역전사 하였다. After slowly pipetting and mixing, the mixture was allowed to stand at room temperature for 20 minutes, and the complex thus prepared was added to a well plate and incubated in a CO 2 cell incubator at 37 ° C. for 24 hours. After 24 hours, total messenger ribonucleic acid (mRNA) present in cells was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and this mRNA was reverse transcribed into cDNA using AccuPowerRT PreMix (Bioneer, Daejeon, Korea). It was.

도 14는 미처리군과 비교예 1과 실시예 24와 38을 사용한 복합체를 처리한 경우 KB 세포내에서 타겟 유전자인 서바이빈의 전사체 발현을 비교한 것이다. 대조군은 미처리군과 비교예 1을 사용하였다. Figure 14 compares the expression of transcripts of survivin, a target gene in KB cells, when untreated group and the complexes using Comparative Example 1 and Examples 24 and 38 were treated. As a control group, Comparative Example 1 and the untreated group were used.

미처리 대조군에 비해 실시예 24와 38을 사용한 복합체 처리군의 경우 서바이빈 유전자의 발현양이 각각 19.2%와 10.3% 같이 현저히 낮은 것으로 확인되어 비교예 1에서 나타난 44.2% 발현양에 비해 서바이빈을 타겟하는 작은간섭 리보핵산의 전달효율이 더 우수한 것으로 확인되었다. In the complex treated group using Examples 24 and 38, the expression level of survivin gene was significantly lower, such as 19.2% and 10.3%, respectively, compared to the untreated control group, compared to the 44.2% expression level shown in Comparative Example 1. It was confirmed that the transfer efficiency of small interfering ribonucleic acid that targets.

이와 같은 결과에서 알 수 있듯이, 실시예 24와 38에서 제조된 핵산 전달체가 KB 세포 내로 작은간섭 리보핵산물질을 비교예 1 보다 더 우수한 효율로 전달하여 표적유전자의 발현을 선택적으로 억제시킴을 알 수 있었다. As can be seen from these results, it can be seen that the nucleic acid carriers prepared in Examples 24 and 38 deliver small interfering ribonucleic acid into KB cells with better efficiency than Comparative Example 1 to selectively inhibit the expression of the target gene. there was.

5-4. K562 세포에서 역전사 중합효소 연쇄반응을 이용한 작은간섭 리보핵산 전달 효능 평가 5-4. Evaluation of Small Interfering Ribonucleic Acid Delivery Efficacy by Reverse Transcription Polymerase Chain Reaction in K562 Cells

K562 세포주를 실험 전날 24 웰 플레이트에 웰 당 세포를 5×10⁴씩 분주(seeding)하였다. 각 플레이트의 세포가 60-70%정도 균일하게 성장했을 때, 에펜 도르프 튜브에 혈청이 포함되지 않은 배지 50㎕씩을 넣고, 서바이빈을 타겟하는 siRNA 20 pmole을 비교예 1 (LipofectamineTM2000과 siRNA 복합체 처리군)과 실시예 4와 실시예 32에서 제조된 핵산 전달체 용액을 무게비가 1:60이 되도록 각각 첨가하였다. 이들을 서서히 피펫팅(pipetting)하여 혼합한 후 실온에서 20분간 방치하고 이렇게 제조된 복합체를 웰 플레이트에 첨가하여 37 ℃의 CO₂세포배양기에서 24시간 동안 배양하였다. 24시간 후 Trizol 시약(Invitrogen, Carlsbad, CA, USA)을 사용하여 세포내에 존재하는 전체 메신저 리보핵산 (mRNA)을 분리하였으며, 이 mRNA는 AccuPowerRT PreMix (Bioneer, Daejeon, Korea)를 사용하여 cDNA로 역전사 하였다. K562 cell lines were seeded 5 × 10 μs of cells per well into 24 well plates the day before the experiment. When the cells of each plate grew uniformly about 60-70%, 50 μl of serum-free medium was added to the Eppendorf tube, and 20 pmoles of siRNA targeting survivin were compared to Comparative Example 1 (LipofectamineTM2000 and siRNA complex treatment). Group) and the nucleic acid carrier solution prepared in Examples 4 and 32 were added so that the weight ratio is 1:60. After slowly pipetting and mixing, the mixture was allowed to stand at room temperature for 20 minutes, and the complex thus prepared was added to a well plate and incubated in a CO 2 cell incubator at 37 ° C. for 24 hours. After 24 hours, total messenger ribonucleic acid (mRNA) present in cells was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and this mRNA was reverse transcribed into cDNA using AccuPowerRT PreMix (Bioneer, Daejeon, Korea). It was.

도 15는 미처리군과 비교예 1과 실시예 4와 32를 사용한 복합체를 처리한 경우 K562 세포내에서 타겟 유전자인 서바이빈의 전사체 발현을 비교한 것이다. 대조군은 미처리군과 비교예 1을 사용하였다. FIG. 15 compares the expression of transcripts of survivin, a target gene, in K562 cells when the untreated group and the complex using Comparative Example 1 and Examples 4 and 32 were treated. FIG. As a control group, Comparative Example 1 and the untreated group were used.

미처리 대조군에 비해 실시예 4와 32를 사용한 복합체 처리군의 경우 서바이빈 유전자의 발현양이 각각 52.6%와 48.1% 같이 낮은 것으로 확인되어 비교예 1에서 나타난 95.3% 발현양에 비해 서바이빈을 타겟하는 작은간섭 리보핵산의 전달효율이 더 우수한 것으로 확인되었다. Compared with the untreated control group, the expression level of survivin gene was lower as 52.6% and 48.1% in the complex treated group using Examples 4 and 32, respectively. It was found that the delivery efficiency of the targeted small interfering ribonucleic acid was better.

이와 같은 결과에서 알 수 있듯이, 실시예 4와 32에서 제조된 핵산 전달체가 K562 세포 내로 작은간섭 리보핵산물질을 비교예 1 보다 더 우수한 효율로 전달하여 표적유전자의 발현을 선택적으로 억제시킴을 알 수 있었다. As can be seen from these results, it can be seen that the nucleic acid carriers prepared in Examples 4 and 32 deliver small interfering ribonucleic acid into K562 cells with better efficiency than Comparative Example 1 to selectively inhibit the expression of the target gene. there was.

[실험예 6] 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)을 사용한 세포독성 평가 Experimental Example 6 Cytotoxicity Evaluation Using 3- (4,5-dimethylthiazole-2-yl) -2,5-diphenyl tetrazolium bromide (MTT)

6-1. WM 266.4 세포주에서의 세포독성 평가 6-1. Cytotoxicity Assessment in WM 266.4 Cell Line

본 발명의 핵산 전달체의 세포 독성에 관한 평가를 하기 위하여 하기와 같은 과정으로 실험을 수행하였다. WM 266.4 세포에 대조군으로 미처리군과 비교예 1 (LipofectamineTM2000과 siRNA 복합체 처리군)을 사용하였으며, 작은 간섭 리보핵산과 실시예 11과 실시예 30에서 제조한 핵산 전달체의 복합체 무게비가 1:60이 되도록 처리하고 세포 독성을 평가하였다. 핵산 전달체만의 세포 독성을 명확히 평가하기 위하여 siRNA는 세포내에서 활성이 없는 스크램블 서열을 사용하였다. 세포 독성은 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 시약에 의한 방법으로 평가하였다. In order to evaluate the cytotoxicity of the nucleic acid carrier of the present invention, the experiment was carried out as follows. WM 266.4 cells were used as a control group in the untreated group and Comparative Example 1 (LipofectamineTM2000 and siRNA complex treated group), so that the complex weight ratio of the small interfering ribonucleic acid and the nucleic acid carriers prepared in Examples 11 and 30 was 1:60. Treatment and cytotoxicity were assessed. In order to clearly assess the cytotoxicity of the nucleic acid carrier only, siRNA used an inert scrambled sequence in the cell. Cytotoxicity was assessed by the method with 3- (4,5-dimethylthiazole-2-yl) -2,5-diphenyl tetrazolium bromide (MTT) reagent.

세포를 웰 당 2.5×104 세포가 되도록 48 웰(well)에 분주 (seeding)하고 12시간 배양한 후 핵산 전달체와 siRNA의 복합체 조성을 처리하였다. 24시간 경과 후 각각 MTT 용액을 배지의 10%가 되도록 가하고, 3시간 더 배양한 다음 상층액을 제거하고 0.04 N 염산 이소프로판올 용액을 첨가한 후에 엘라이져 리더 (ELISA reader, Sunrise-Basic TECAN, Mannedorf, Switzerland)를 이용하여 570 nm에서 그 흡광도를 측정하였다. Cells were seeded in 48 wells for 2.5 × 10 4 cells per well, incubated for 12 hours, and then treated with a complex composition of the nucleic acid carrier and siRNA. After 24 hours, each MTT solution was added to 10% of the medium, incubated for another 3 hours, the supernatant was removed, and then 0.04 N isopropanol solution was added, followed by ELISA reader, Sunrise-Basic TECAN, Mannedorf, Its absorbance was measured at 570 nm.

도 16으로부터 실시예 11과 실시예 30에서 제조된 본 발명의 핵산 전달체는 사람의 피부 흑색종 세포에 대해 비교예 1 보다 더 낮은 독성을 갖는다는 사실을 알 수 있다. It can be seen from FIG. 16 that the nucleic acid carriers of the present invention prepared in Examples 11 and 30 have a lower toxicity than that of Comparative Example 1 on human cutaneous melanoma cells.

6-2. HeLa 세포주에서의 세포독성 평가 6-2. Cytotoxicity Assessment in HeLa Cell Line

본 발명의 핵산 전달체의 세포 독성에 관한 평가를 하기 위하여 하기와 같은 과정으로 실험을 수행하였다. HeLa 세포에 대조군으로 미처리군과 비교예 1 (LipofectamineTM2000과 siRNA 복합체 처리군)을 사용하였으며, 작은 간섭 리보핵산과 실시예 14와 34에서 제조한 핵산 전달체의 복합체 무게비가 1:60이 되도록 처리하고 세포 독성을 평가하였다. 핵산 전달체만의 세포 독성을 명확히 평가하기 위하여 siRNA는 세포내에서 활성이 없는 스크램블 서열을 사용하였다. 세포 독성은 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 시약에 의한 방법으로 평가하였다. In order to evaluate the cytotoxicity of the nucleic acid carrier of the present invention, the experiment was carried out as follows. As a control, HeLa cells were treated with an untreated group and Comparative Example 1 (LipofectamineTM2000 and siRNA complex treated group), and treated so that the complex weight ratio of the small interfering ribonucleic acid and the nucleic acid carrier prepared in Examples 14 and 34 was 1:60. Toxicity was evaluated. In order to clearly assess the cytotoxicity of the nucleic acid carrier only, siRNA used an inert scrambled sequence in the cell. Cytotoxicity was assessed by the method with 3- (4,5-dimethylthiazole-2-yl) -2,5-diphenyl tetrazolium bromide (MTT) reagent.

세포를 웰 당 2.5×104 세포가 되도록 48 웰(well)에 분주 (seeding)하고 12시간 배양한 후 핵산 전달체와 siRNA의 복합체 조성을 처리하였다. 24시간 경과 후 각각 MTT 용액을 배지의 10%가 되도록 가하고, 3시간 더 배양한 다음 상층액을 제거하고 0.04 N 염산 이소프로판올 용액을 첨가한 후에 엘라이져 리더 (ELISA reader, Sunrise-Basic TECAN, Mannedorf, Switzerland)를 이용하여 570 nm에서 그 흡광도를 측정하였다. Cells were seeded in 48 wells for 2.5 × 10 4 cells per well, incubated for 12 hours, and then treated with a complex composition of the nucleic acid carrier and siRNA. After 24 hours, each MTT solution was added to 10% of the medium, incubated for another 3 hours, the supernatant was removed, and then 0.04 N isopropanol solution was added, followed by ELISA reader, Sunrise-Basic TECAN, Mannedorf, Its absorbance was measured at 570 nm.

도 17로부터 실시예 14와 실시예 34에서 제조된 본 발명의 핵산 전달체는 사람의 자궁 경부암 상피세포에 대해 비교예 1 보다 낮은 독성을 갖는다는 사실을 알 수 있다. It can be seen from FIG. 17 that the nucleic acid carriers of the present invention prepared in Examples 14 and 34 have a lower toxicity than that of Comparative Example 1 with respect to human cervical cancer epithelial cells.

도 1는 핵자기 공명법 (NMR)을 사용하여 본 발명의 핵산 전달체의 합성 여부를 확인한 결과를 보여준다. Figure 1 shows the results of confirming the synthesis of the nucleic acid carrier of the present invention using nuclear magnetic resonance (NMR).

도 2은 적외선 흡수 스펙트럼 분석법 (FT-IR)을 사용하여 본 발명의 핵산 전달체의 합성 여부를 확인한 결과를 보여준다. Figure 2 shows the results of confirming the synthesis of the nucleic acid carrier of the present invention using infrared absorption spectrum analysis (FT-IR).

도 3은 작은 간섭 리보핵산을 사용하여 본 발명의 핵산 전달체와 결합체를 형성하는지 여부를 아가로즈 젤 전기영동 방법을 이용하여 확인한 결과이다. Figure 3 is a result confirmed using agarose gel electrophoresis method to form a conjugate with the nucleic acid carrier of the present invention using a small interfering ribonucleic acid.

도 4는 작은 간섭 리보핵산을 사용하여 본 발명의 핵산 전달체와 결합체를 형성한 후 결합체의 크기를 동적광산란 장비를 이용하여 측정한 결과이다. Figure 4 is a result of measuring the size of the conjugate using a dynamic light scattering equipment after forming a conjugate with the nucleic acid carrier of the present invention using a small interfering ribonucleic acid.

도 5은 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 사람의 자궁경부암 세포인 HeLa에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율을 보여주는 사진이다. Figure 5 is a photograph showing the intracellular nucleic acid transfer efficiency of the nucleic acid carrier of the present invention in HeLa, a human cervical cancer cell using small interfering ribonucleic acid labeled with fluorescent labels.

도 6는 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 쥐의 간암 세포인 Hepa 1-6에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율을 보여주는 사진이다. Figure 6 is a photograph showing the intracellular nucleic acid delivery efficiency of the nucleic acid carrier of the present invention in Hepa 1-6, a mouse liver cancer cell using small interfering ribonucleic acid labeled with a fluorescent label.

도 7는 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 사람의 피부 흑색종 세포인 WM 266.4에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율을 보여주는 사진이다. FIG. 7 is a photograph showing the intracellular nucleic acid delivery efficiency of the nucleic acid carrier of the present invention in human skin melanoma cells WM 266.4 using small interfering ribonucleic acid labeled with fluorescent labels.

도 8은 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 사람의 폐암 세포인 A549 세포에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율 정도를 형 광 유세포분석기 (FACS)를 사용해 분석한 결과이다. 8 is a result of analyzing the degree of intracellular nucleic acid transfer efficiency of the nucleic acid delivery agent of the present invention in A549 cells, which are human lung cancer cells, using small interfering ribonucleic acid labeled with a fluorescent label using a fluorescent flow cytometer (FACS).

도 9는 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 사람의 케라틴 분비형 자궁경부암 세포인 KB세포에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율 정도를 형광 유세포분석기 (FACS)를 사용해 분석한 결과이다. 9 is analyzed by using a fluorescent flow cytometer (FACS) of the intracellular nucleic acid delivery efficiency of the nucleic acid carrier of the present invention in KB cells, human keratin-secreting cervical cancer cells using small interfering ribonucleic acid with a fluorescent label The result is.

도 10은 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 사람의 혈액성 백혈병 세포인 K562세포에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율 정도를 형광 유세포분석기 (FACS)를 사용해 분석한 결과이다. 10 is a result of analyzing the intracellular nucleic acid transfer efficiency of the nucleic acid carrier of the present invention in K562 cells, which are human hematological leukemia cells, using small interfering ribonucleic acid labeled with a fluorescent label using a fluorescent flow cytometer (FACS). .

도 11은 형광 표식이 붙어있는 작은 간섭 리보핵산을 사용하여 사람의 골수성 백혈병 세포인 TF-1세포에서 본 발명의 핵산 전달체의 세포내 핵산 전달 효율 정도를 형광 유세포분석기 (FACS)를 사용해 분석한 결과이다. 11 is a result of analyzing the intracellular nucleic acid transfer efficiency of the nucleic acid carrier of the present invention using fluorescence flow cytometry (FACS) in TF-1 cells, which are human myeloid leukemia cells, using small interfering ribonucleic acid labeled with fluorescent labels to be.

도 12는 본 발명의 핵산 전달체를 이용하여 서바이빈 발현 억제 작은 간섭 리보핵산에 의해 매개된 서바이빈 전사체 발현 억제 효능을 사람의 자궁경부암 세포인 HeLa 세포에서 역전사 중합효소 연쇄반응으로 확인한 결과를 보여준다. Figure 12 shows the effect of inhibiting the expression of survivin transcripts mediated by small interfering ribonucleic acid using a nucleic acid carrier of the present invention by reverse transcriptase polymerase chain reaction in HeLa cells, human cervical cancer cells Shows.

도 13은 본 발명의 핵산 전달체를 이용하여 서바이빈 발현 억제 작은 간섭 리보핵산에 의해 매개된 서바이빈 전사체 발현 억제 효능을 사람의 피부 흑색종 세포인 WM 266.4 세포에서 역전사 중합효소 연쇄반응으로 확인한 결과를 보여준다. FIG. 13 shows the effect of inhibiting survivin expression using a nucleic acid carrier of the present invention. Show the result.

도 14는 본 발명의 핵산 전달체를 이용하여 서바이빈 발현 억제 작은 간섭 리보핵산에 의해 매개된 서바이빈 전사체 발현 억제 효능을 사람의 케라틴 분비형 자궁경부암 세포인 KB세포에서 역전사 중합효소 연쇄반응으로 확인한 결과를 보여준다. FIG. 14 shows the reverse transcriptase polymerase chain reaction in the KB cells of human keratin-secreting cervical cancer cells, which inhibits survivin expression inhibition mediated by small interfering ribonucleic acid using the nucleic acid carrier of the present invention. Shows the result.

도 15는 본 발명의 핵산 전달체를 이용하여 서바이빈 발현 억제 작은 간섭 리보핵산에 의해 매개된 서바이빈 전사체 발현 억제 효능을 사람의 혈액성 백혈병 세포인 K562세포에서 역전사 중합효소 연쇄반응으로 확인한 결과를 보여준다. 15 shows the suppression of survivin transcript expression mediated by small interfering ribonucleic acid using the nucleic acid delivery agent of the present invention, which was confirmed by reverse transcriptase polymerase chain reaction in K562 cells of human hematological leukemia cells. Show results.

도 16은 MTT 염색법을 사용하여 본 발명의 핵산 전달체의 세포독성을 사람의 피부 흑색종 세포인 WM 266.4에서 확인한 결과를 보여준다. Figure 16 shows the results of confirming the cytotoxicity of the nucleic acid carrier of the present invention in the WM 266.4 human skin melanoma cells using MTT staining.

도 17은 MTT 염색법을 사용하여 본 발명의 핵산 전달체의 세포독성을 사람의 자궁경부암 세포인 HeLa에서 확인한 결과를 보여준다.17 shows the results of confirming the cytotoxicity of the nucleic acid carrier of the present invention in HeLa, a human cervical cancer cell using MTT staining.

Claims (20)

하기 화학식 1 또는 화학식 2의 구조를 가지는 양이온성 키토산 유도체:A cationic chitosan derivative having the structure of Formula 1 or Formula 2 below: [화학식 1][Formula 1]
Figure 112009058456483-pat00008
Figure 112009058456483-pat00008
 [화학식 2][Formula 2]
Figure 112009058456483-pat00009
Figure 112009058456483-pat00009
 상기 식에서 R은 레티놀(retinol), 9-시스-레티놀산(9-cis-retinoic acid), 13-시스-레티놀산(13-cis-retinoic acid), 올-트랜스-레티놀산(all-trans-retinoic acid), 에르고칼시페롤(ergocalciferol, vitamin D2), 비타민 D2 (6,19,19-d3)(Vitamin D2 (6,19,19-d3)), 콜레칼시페롤(cholecalciferol, vitamin D3), 비타민 D3 (6,19,19-d3)(vitamin D3 (6,19,19-d3)), (±)-알파-토코페롤((±)-α-tocopherol), (+)-알파-토코페롤((+)-α-tocopherol), (+)-베타-토코페롤((+)-β-tocopherol), 감마-토코페롤((+)-γ-tocopherol), 델타-토코페롤((+)-δ-tocopherol), 알파-토코페롤 숙시네이트(D-α-tocopherol succinate), 알파-토코페롤 폴리에틸렌글리콜(D-α-tocopherol polyethylene glycol), 알파-토코트리엔올(D-α-tocotrienol), (+)-베타-토코트리엔올((+)-β-tocotrienol), 델타-토코트리엔올(D-δ-tocotrienol), 및 감마-토코트리엔올(D-γ-tocotrienol)로 이루어진 그룹 중에서 선택된 비타민 또는 그 유도체로부터 유도된 유기기를 나타내며, Wherein R is retinol, 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid retinoic acid), ergocalciferol (vitamin D2), vitamin D2 (6,19,19-d3) (Vitamin D2 (6,19,19-d3)), cholecalciferol (vitamin D3) , Vitamin D3 (6,19,19-d3) (vitamin D3 (6,19,19-d3)), (±) -alpha-tocopherol ((±) -α-tocopherol), (+)-alpha-tocopherol ((+)-α-tocopherol), (+)-beta-tocopherol ((+)-β-tocopherol), gamma-tocopherol ((+)-γ-tocopherol), delta-tocopherol ((+)-δ- tocopherol), alpha-tocopherol succinate, alpha-tocopherol polyethylene glycol, alpha-tocotrienol, (+)- Vitamins selected from the group consisting of beta-tocotrienol ((+)-β-tocotrienol), delta-tocotrienol, and gamma-tocotrienol (D-γ-tocotrienol) or It represents an organic derivatives derived from, L은 -CONH- 또는 -NHCOO-을 나타내고,L represents -CONH- or -NHCOO-, M은 -COO- 또는 -O(CH2)2O-를 나타내며, M represents -COO- or -O (CH 2 ) 2 O-, X는 아세틸기, 메틸글리콜기, 갈락토실기, 락토실기 또는 말토실기를 나타내고,X represents an acetyl group, methyl glycol group, galactosyl group, lactosyl group or maltosyl group, a 및 b는 각각 독립적으로 1 내지 150의 정수를 나타내며, a and b each independently represent an integer of 1 to 150, c는 0 내지 50의 정수를 나타낸다.c represents the integer of 0-50. 삭제delete 삭제delete 제1항에 있어서 The method of claim 1 c는 0인 양이온성 키토산 유도체.c is 0 a cationic chitosan derivative. 제1항에 있어서, The method of claim 1, c는 1 내지 50이고, X는 갈락토실, 락토실 또는 말토실을 나타내는 양이온성 키토산 유도체. c is 1 to 50 and X represents a galactosyl, lactosyl or maltosyl. 제1항에 있어서, The method of claim 1, a와 b의 합이 2 내지 50이고, the sum of a and b is 2 to 50, R은 9-시스-레티놀산(9-cis-retinoic acid), 13-시스-레티놀산(13-cis-retinoic acid), 올-트랜스-레티놀산(all-trans-retinoic acid), (±)-알파-토코페롤((±)-α-tocopherol), 알파-토코페롤 숙시네이트(D-α-tocopherol succinate), (+)-알파-토코페롤((+)-α-tocopherol), 알파-토코페롤 폴리에틸렌글리콜(D-α-tocopherol polyethylene glycol), 및 알파-토코트리엔올(D-α-tocotrienol)로 이루어진 그룹 중에서 선택된 비타민 또는 그 유도체로부터 유도된 유기기를 나타내는 양이온성 키토산 유도체.R is 9-cis-retinoic acid, 13-cis-retinoic acid, all-trans-retinoic acid, (±) -Alpha-tocopherol ((±) -α-tocopherol), alpha-tocopherol succinate, (+)-alpha-tocopherol ((+)-α-tocopherol), alpha-tocopherol polyethylene glycol (D-α-tocopherol polyethylene glycol), and cationic chitosan derivatives exhibiting organic groups derived from vitamins or derivatives thereof selected from the group consisting of D-α-tocotrienol. 용매의 존재 하에, 커플링제(coupling agent) 또는 보호기를 사용하여 키토산을 지용성 비타민과 반응시키는 단계를 포함하는 제1항의 양이온성 키토산 유도체의 제조방법.A method for preparing the cationic chitosan derivative of claim 1 comprising reacting chitosan with a fat soluble vitamin using a coupling agent or protecting group in the presence of a solvent. 제7항에 있어서,The method of claim 7, wherein 커플링제(coupling agent)는 EDC(N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide), DCC(Dicyclohexylcarbodiimide), DIC(diisopropylcarbodiimide), CDI(1,1'-Carbonyldiimidazole), 숙신이미딜 포밀벤조산(SFB, succinimidyl 4-formylbenzoate), C6-숙신이미딜 포밀벤조산(C6-SFB, C6-succinimidyl 4-formylbenzoate), 디숙신이미딜 글루탐산(DSG, Disuccinimidyl glutarate), 디숙신이미딜 수베르산(DSS, Disuccinimidyl suberate), 비스설포숙신이미딜 수베르산(BS3, Bis[sulfosuccinimidyl] suberate), HOBt(N-Hydroxybenzotriazole), 무수숙신산(succinic anhydride), NHS(N-hydroxysuccinimide) 및 sulfo-NHS로 이루어진 그룹 중에서 선택된 하나 이상인 양 이온성 키토산 유도체의 제조방법.Coupling agents include EDC (N- (2-dimethylaminopropyl) -N'-ethylcarbodiimide), DCC (Dicyclohexylcarbodiimide), DIC (diisopropylcarbodiimide), CDI (1,1'-Carbonyldiimidazole), succinimidyl formylbenzoic acid (SFB , succinimidyl 4-formylbenzoate), C6-succinimidyl formylbenzoate (C6-SFB, C6-succinimidyl 4-formylbenzoate), disuccinimidyl glutarate (DSG, Disuccinimidyl glutarate), disuccinimidyl suveric acid (DSS, Disuccinimidyl suberate), bissulfosuccinimidyl subberate (BS3, Bis [sulfosuccinimidyl] suberate), HOBt (N-Hydroxybenzotriazole), succinic anhydride, NHS (N-hydroxysuccinimide) and sulfo-NHS A process for preparing at least one cationic chitosan derivative. 제7항에 있어서,The method of claim 7, wherein 보호기는 무수프탈산인 것을 특징으로 하는 양이온성 키토산 유도체의 제조방법.A protecting group is a method for producing a cationic chitosan derivative, characterized in that phthalic anhydride. 제7항에 있어서,The method of claim 7, wherein 반응은 친핵성 촉매의 존재 하에 진행되는 양이온성 키토산 유도체의 제조방법.A process for producing a cationic chitosan derivative wherein the reaction proceeds in the presence of a nucleophilic catalyst. 제10항에 있어서,The method of claim 10, 친핵성 촉매는 DMAP(4-(Dimethylamino)pyridine)인 양이온성 키토산 유도체의 제조방법.A nucleophilic catalyst is DMAP (4- (Dimethylamino) pyridine) method for producing a cationic chitosan derivative. 약제학적 유효성분; 및Pharmaceutical active ingredients; And 제1항의 양이온성 키토산 유도체를 포함하는 약물 전달체.A drug carrier comprising the cationic chitosan derivative of claim 1. 제12항에 있어서, The method of claim 12, 약제학적 유효성분은 핵산인 약물 전달체.Pharmaceutically active ingredient is a nucleic acid drug delivery. 제13항에 있어서, The method of claim 13, 핵산은 올리고 핵산인 약물 전달체.The drug carrier is a nucleic acid is an oligonucleotide. 제13항에 있어서, The method of claim 13, 핵산은 플라스미드 데옥시리보핵산 (plasmid DNA), 리보핵산(RNA), 작은 간섭 리보핵산(siRNA), 안티센스 올리고핵산(antisense oligonucleotide), 마이크로 리보핵산 (microRNA), 잠금형 핵산 (locked nucleic acid) 및 핵산 앱타머(aptamer)로 이루어진 군으로부터 선택되는 하나 이상인 약물 전달체.Nucleic acids include plasmid deoxyribonucleic acid (RNA), ribonucleic acid (RNA), small interfering ribonucleic acid (siRNA), antisense oligonucleotide, microribonucleic acid (microRNA), locked nucleic acid and At least one drug delivery agent selected from the group consisting of nucleic acid aptamers. 삭제delete 삭제delete 제12항에 있어서, The method of claim 12, 약물 전달체는 리포좀, 미셀, 에멀젼, 또는 나노입자의 제형을 가지는 약물 전달체. The drug carrier is a drug carrier having a formulation of liposomes, micelles, emulsions, or nanoparticles. 제12항의 약물 전달체; 및A drug carrier of claim 12; And 약제학적으로 허용 가능한 담체를 포함하는 의약 조성물. A pharmaceutical composition comprising a pharmaceutically acceptable carrier. 기재;materials; 상기 기재 상에 코팅된 제1항의 양이온성 키토산 유도체; 및The cationic chitosan derivative of claim 1 coated on the substrate; And 상기 양이온성 키토산 유도체와 결합된 핵산 앱타머를 포함하는 진단 키트.Diagnostic kit comprising a nucleic acid aptamer coupled with the cationic chitosan derivative.
KR1020090038844A 2009-05-04 2009-05-04 Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same KR100930326B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020090038844A KR100930326B1 (en) 2009-05-04 2009-05-04 Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same
PCT/KR2010/002838 WO2010128793A2 (en) 2009-05-04 2010-05-04 Fat soluble vitamin and a derivative thereof induced by novel cationic chitosan, a method of producing same and drug delivery system containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090038844A KR100930326B1 (en) 2009-05-04 2009-05-04 Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same

Publications (1)

Publication Number Publication Date
KR100930326B1 true KR100930326B1 (en) 2009-12-08

Family

ID=41683934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090038844A KR100930326B1 (en) 2009-05-04 2009-05-04 Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same

Country Status (2)

Country Link
KR (1) KR100930326B1 (en)
WO (1) WO2010128793A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012152910A1 (en) * 2011-05-12 2012-11-15 Helmut Vockner Novel pharmaceutical formulation
CN102924625A (en) * 2012-11-26 2013-02-13 中国药科大学 Active tumor targeting chitosan derivative as well as preparation method and application thereof
WO2016068523A3 (en) * 2014-10-29 2017-04-27 가톨릭대학교 산학협력단 Vascular drug-eluting balloon comprising fat-soluble additive and drug and method for manufacturing same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070072301A (en) * 2005-12-29 2007-07-04 나재운 Retinol encapsulated low molecular water-soluble chitosan nanoparticles and method for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997887A (en) * 1997-11-10 1999-12-07 The Procter & Gamble Company Skin care compositions and method of improving skin appearance
KR20020088864A (en) * 2001-05-22 2002-11-29 도영수 Functional bath additive composition made of chitosan and processing therefore
US9265792B2 (en) * 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070072301A (en) * 2005-12-29 2007-07-04 나재운 Retinol encapsulated low molecular water-soluble chitosan nanoparticles and method for preparation thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012152910A1 (en) * 2011-05-12 2012-11-15 Helmut Vockner Novel pharmaceutical formulation
CN102924625A (en) * 2012-11-26 2013-02-13 中国药科大学 Active tumor targeting chitosan derivative as well as preparation method and application thereof
WO2016068523A3 (en) * 2014-10-29 2017-04-27 가톨릭대학교 산학협력단 Vascular drug-eluting balloon comprising fat-soluble additive and drug and method for manufacturing same

Also Published As

Publication number Publication date
WO2010128793A3 (en) 2011-03-24
WO2010128793A2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
Zhao et al. Selectivity of folate conjugated polymer micelles against different tumor cells
US11548857B2 (en) Biodegradable compound, lipid particle, composition comprising lipid particle, and kit
Jain et al. Recent advances in galactose-engineered nanocarriers for the site-specific delivery of siRNA and anticancer drugs
Chen et al. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation
Wang et al. Synthesis and characterization of cationic polymeric nanoparticles as simvastatin carriers for enhancing the osteogenesis of bone marrow mesenchymal stem cells
WO2009021728A2 (en) Targeted block copolymer micelles
Mirzaie et al. Docetaxel–chitosan nanoparticles for breast cancer treatment: cell viability and gene expression study
US9745421B2 (en) Dendronized polymers for nucleic acid delivery
Li et al. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation
US20050153913A1 (en) Nucleic acid carrier compositions and methods for their synthesis
CN110506035B (en) Biodegradable compound, lipid particle, composition containing lipid particle, and kit
Hussein et al. Peptide-based targeted polymeric nanoparticles for siRNA delivery
Scott et al. Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity
Xiang et al. tLyp-1-conjugated GSH-sensitive biodegradable micelles mediate enhanced pUNO1-hTRAILa/curcumin co-delivery to gliomas
KR100930326B1 (en) Fat-soluble vitamin-derived novel cationic chitosan, a preparation method of the same and a drug delivery system comprising the same
Mostoufi et al. Reversing multi-drug tumor resistance to Paclitaxel by well-defined pH-sensitive amphiphilic polypeptide block copolymers via induction of lysosomal membrane permeabilization
CN112843241A (en) Biologically-responsive nitric oxide donor type polymer prodrug and preparation method thereof
WO2020078216A1 (en) Nucleic acid nanocarrier medicine and preparation method therefor
US20060040879A1 (en) Chloroquine coupled nucleic acids and methods for their synthesis
Ji et al. A targeted nanocarrier based on polyspermine for the effective delivery of methotrexate in nasopharyngeal carcinoma
Xu et al. Novel polymeric hybrid nanocarrier for curcumin and survivin shRNA co-delivery augments tumor penetration and promotes synergistic tumor suppression
Zhou et al. Multifunctional triblock co-polymer mP3/4HB-b-PEG-b-lPEI for efficient intracellular siRNA delivery and gene silencing
Issarachot et al. Folic acid-modified methotrexate-conjugated PEGylated poly (ε-caprolactone) nanoparticles for targeted delivery
CN111150852B (en) Cisplatin-containing medicine, preparation method thereof, pharmaceutical composition and application thereof
JP2023500602A (en) Peptide-Nanoparticle Conjugates Cross-reference to Related Applications Priority is claimed from US Provisional Application No. 62/927,293, which is incorporated herein by reference in its entirety.

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121004

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20130717

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee